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ABSTRACT 
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Liver cancer is the fifth most common cancer in the world. Until recently, tumor 
cells were known to have the capacity to proliferate indefinitely. In a previous 
study, we showed the spontaneous induction of replicative senescence in p53-
and p16INK4a-deficient HCC (hepatocellular carcinoma) cells. In a follow-up 
study, we have analyzed the Affymetrix expression profiling of the senescent 
and immortal HCC clones that we had established. Among the genes with 
differential expression pattern, in this study, we have focused on a novel gene, 
FAM134B (family with sequence similarity 134, member B), which is 
significantly up-regulated (p-value=1.097E-06) in our senescent clones with 
respect to their immortal counterparts. FAM134B gene is located on human 
chromosome 5p15.1 near a LOH region, and its protein product has not yet been 
characterized. To begin with, we confirmed the up-regulation of FAM134B in 
our senescent clones as compared to our immortal clones by RT-PCR analysis. 
As a next step, meta-analysis of HCC microarray data indicated that the 
expression of FAM134B gene is progressively down-regulated in non-metastatic 
and metastatic HCC as compared to normal liver. Thus, we decided to 
characterize the protein product of this gene. Two known forms of transcripts 
were used to construct FLAG-tagged expression plasmids (encoding two 
isoforms with predicted molecular weights of 30 and 55 kDa). Immuno-staining 
experiments performed after transient ectopic expression indicated that both 
short and long isoforms of FAM134B-encoded protein localize to the 
endoplasmic reticulum (ER). Both protein isoforms co-localized with calnexin, a 
well known ER-chaperon. Thus, it appears that senescent cells over-express 
FAM134B-encoded ER protein isoforms, while cancer cells are deficient in their 
expression. We have also performed gain-of-function studies by stable ectopic 
expression of these two protein isoforms in an HCC cell line and addressed the 
potential role(s) of these isoforms in senescence and ER-stress. Our studies 
indicated that over-expression of these proteins did not have a ‘causative’ role in 
induction of senescence and did not affect the rate of cell proliferation. We also 
did not observe any changes in the responses of cells over-expressing these two 
protein isoforms to ER-stress induced via tunicamycin treatment. Therefore, 
FAM134B gene may be performing a yet unidentified function in senescent 
cells. All in all, we have identified two FAM134B-encoded proteins that localize 
to the ER, the function and the senescence association of which need further 
investigation.   
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ÖZET 
HÜCRE YAŞLANMASIYLA İLİNTLİ FAM134B GENİ TARAFINDAN 
KODLANAN İKİ ENDOPLASMİK RETİKULUM PROTEİN 
İZOFORMUNUN BELİRLENMESİ VE KARAKTERİZASYONU 
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Temmuz 2008, 112 Sayfa 
 
 
Karaciğer kanseri dünyada beşinci sıklıkla görülen kanser türüdür. Yakın bir 
zamana kadar, tümör hücrelerinin sonsuz bölünebilme kapasitesine sahip olduğu 
düşünülmekteydi. Önceki çalışmalarımızın birinde, p53 ve p16INK4a 
proteinlerinden yoksun olan karaciğer kanseri hücre hatlarında kendiliğinden 
gelişen hücre yaşlanmasını gösterdik. Bunu takip eden bir çalışmada, elde etmiş 
olduğumuz senesant ve ölümsüz klonlarin Affymetrix gen ifade profillerini 
inceledik. Klonlarda ifadesi fark gösteren genler arasından, bu çalışmada, yeni 
bir gen olan ve senesant klonlarda ölümsüz klonlara göre ifadesi istatistiksel 
olarak anlamlı artış gösteren (p-değeri=1.097E-06) FAM134B geni üzerinde 
yoğunlaştık. FAM134B geni beşinci insan kromozomunun p15.1 bölgesi 
üzerinde yer almaktadır ve kodladığı protein ürünü henüz karakterize 
edilmemiştir. Başlangıç olarak, revers transkriptaz polimeraz zincir reaksiyonu 
kullanarak FAM134B geninin senesant klonlarda ölümsüz klonlara göre ifade 
artışını doğruladık. Bir sonraki adımda, hepatosellüler karsinoma mikro-
dizinlerinin meta-analizi, FAM134B geninin ifadesinin normal karaciğer 
dokusuna göre metastatik olmayan ve metastatik hepatosellüler karsinomada 
dereceli olarak azaldığını gösterdi. Bu nedenle, bu genin protein ürününü 
karakterize etmeye karar verdik. Bilinen iki transkript formu kullanılarak 
(tahmini moleküler ağırlıkları 30 ve 50 kDa olan iki izofomu kodlayan) FLAG-
işaretli ifade vektörleri oluşturuldu. Hücrelerde bu vektörlerin geçici ifadesi 
sonrasında yapılan immüno-boyama deneyleri, hem uzun hem kisa FAM134B 
protein izoformlarının  endoplazmik retikuluma lokalize olduğunu gösterdi. Her 
iki protein izoformu, iyi bilinen bir endoplozmik retikulum şaperonu olan 
kalneksin proteini ile ortak lokalizasyon gösterdi. Buradan anlaşıldığı gibi, 
senesant hücrelerde endoplazmik retikuluma lokalize olan FAM134B protein 
izoformlarınn ifadesi artarken, kanser hücreleri bu izoformlarin ifadesinden 
yoksundular. Ayrica, bu iki protein izoformunun bir karaciğer kanseri hücre 
hattında sürekli ifadesi yoluyla işlev-kazanım deneyleri yaptık. bu protein 
izoformlarının senesansta ve endoplazmik retikulum stresindeki potansiyel rol 
veya rollerini sorguladık. Çalışmalarımızın sonuçları, bu protein izoformlarinin 
hücrelerde yüksek seviyedeki ifadesinin senesans indüklenmesine yol açacak bir 
rol oynamadığı ve hücrelerin bölünme hızını değiştirmediği yönünde bilgi verdi. 
Ayrica bu iki izoformu yüksek seviyede ifade eden hücrelerin tunikamisin ile 
indükenen endoplazmik retikulum stresine karşı yanıtlarında bir değişiklik 
gözlemlemedik. Dolayısıyla, FAM134B geninin senesansa girmiş olan 
hücrelerde henüz tanımlayamadığımız bir işlevi söz konusu olabilir. Sonuç 
 v 
olarak, FAM134B tarafından kodlanan ve endoplazmik retikuluma lokalize olan 
iki protein izoformu belirledik ve bu izoformların hücre içindeki görevleri ve 
senesansla olan bağlarının ilerki çalışmalarla ortaya koyulması gerekmektedir.  
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CHAPTER 1. INTRODUCTION 
 
1.1 Hepatocellular Carcinoma  
Liver cancer comprises diverse, histologically distinct primary hepatic 
neoplasms, which include hepatocellular carcinoma (HCC), intrahepatic bile 
duct carcinoma (cholangiocarcinoma), hepatoblastoma, bile duct 
cystadenocarcinoma, haemangiosarcoma and epitheliod haemangioendothelioma 
(Anthony P. et al., 2002). Among these, HCC is the most common type of liver 
cancer, representing 83% of all cases (American Cancer Society, 2005). It is also 
one of the most lethal cancers, and affects many of the world’s populations 
(Farazi PA. and DePinho RA., 2006). 
HCCs are phenotypically (morphology and microscopy) and genetically 
heterogenous tumors, possibly reflecting in part the heterogeneity of etiologic 
factors implicated in HCC development, the complexity of hepatocyte functions 
and the late stage at which HCCs usually become clinically symptomatic and 
detectable. Malignant transformation of hepatocytes may occur regardless of the 
etiologic agent through a pathway of increased liver cell turnover, induced by 
chronic liver injury and regeneration in a context of inflammation, immune 
response, and oxidative DNA damage. This may result in genetic alterations, 
such as activation of cellular oncogenes, inactivation of tumor suppressor genes, 
possibly in cooperation with genomic instability, including  DNA mismatch 
repair defects and impaired chromosomal segregation, over-expression of growth 
and angiogenic factors, and telomerase activation (Ozturk M. et al., 1999; 
Bergsland EK. et al., 2001; Thorgeirsson SS. and Grisham JW., 2002; Block 
TM. et al., 2003; Brechot C. et al., 2004; Satyanarayana A. et al., 2004; 
Suriawinata A. and Xu R., 2004; Yu MC. and Yuan JM., 2004; Blum Hubert E. 
et al., 2005).    
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1.2 Pathogenesis of hepatocellular carcinoma 
The neoplastic evolution of HCC proceeds through a multi-step 
histological process that is less well defined than that of other cancer types 
(Figure 1.1). Diverse HCC-inducing aetiologies provoke continuous rounds of 
hepatocyte damage and regeneration, culminating in chronic liver disease. As a 
next step, hepatocyte proliferative arrest leads to liver cirrhosis. Cirrhosis of the 
liver is a premalignant state and a major histopathological risk factor for HCC 
development, since more than 80 percent of HCC in the western world develop 
in a cirrhotic liver (Edmondson HA., Peters RL., 1983). Abnormal liver nodules 
of the cirrhotic liver go on to develop into hyperplastic nodules. Hyperplastic 
nodules of regenerating hepatocytes have normal cytological features, and 
represent a potential first step towards HCC. 
 
Farazi PA. and DePinho RA., 2006 
 
Figure 1.1: Histopathological progression and molecular features of HCC. After hepatic 
injury incurred by any one of several factors (HBV, HCV, alcohol and aflatoxin B1), there is 
necrosis followed by hepatocyte proliferation. Continuous cycles of this destructive–regenerative 
process foster a chronic liver disease condition that culminates in liver cirrhosis. Subsequently, 
hyperplastic nodules are observed, followed by dysplastic nodules and ultimately hepatocellular 
carcinoma (HCC) Telomere shortening, loss and/or mutation of p53 and genomic instability also 
characterize hepatocarcinogenesis. (Farazi PA. and DePinho RA., 2006). 
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These lesions can progress to pre-malignant dysplastic nodules, which 
have abnormal cytological features including clear cell changes and nuclear 
crowding, and these lesions are associated with the increased thickening of the 
trabeculae, which indicates abnormal liver architecture (Farazi PA. and DePinho 
RA., 2006). These dysplastic nodules can evolve to frank HCC which, in 
addition to all the aforementioned abnormal features, is endowed with the 
capacity to invade the surrounding fibrous stroma and vessels, and occasionally 
has metastatic potential (Okuda  K. et al., 2000). 
1.3 Aetiologies of hepatocellular carcinoma 
The most prominent factors associated with HCC include chronic 
hepatitis B and C viral infection, chronic alcohol consumption, aflatoxin-B1-
contaminated food and virtually all cirrhosis-inducing conditions (Badvie S., 
2000). In addition, gender can also influence the risk and behaviour of HCC, 
with males accounting for a larger fraction of cases (Sherman M., 2005). The 
suspected mechanisms of hepatocarcinogenesis for the various risk factors are 
summarized in Figure 1.2. 
 
Farazi PA. and DePinho RA., 2006 
Figure 1.2: Mechanisms of hepatocarcinogenesis. The suspected mechanisms of 
hepatocarcinogenesis for the various risk factors are shown. Commonalities are indicated using 
the same colour. In addition to these mechanisms, hepatitis B virus (HBV) and aflatoxin B1 
share the characteristic of affecting the genome — HBV can integrate into the host genome and 
aflatoxin B1 is a mutagen. HCV, hepatitis C virus (Farazi PA. and DePinho RA., 2006). 
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1.3.1 Viral-induced hepatocarcinogenesis 
There are two main hepatitis viruses associated with the development of 
HCC: Hepatitis B virus (HBV) and Hepatitis C virus (HCV).  Approximately 
30–50% of HBV-related deaths are attributable to HCC (Lavanchy D., 2004). 
HBV-induced hepatocarcinogenesis can involve an array of processes, including 
host–viral interactions, sustained cycles of necrosis–inflammation–regeneration, 
viral–endoplasmic-reticulum interactions (induction of oxidative stress), viral 
integration into the host genome (and associated host DNA deletions) and the 
targeted activation of oncogenic pathways by various viral proteins (Farazi PA. 
and DePinho RA., 2006). Hepatitis C virus (HCV) infects approximately 170 
million individuals worldwide (Chisari F. V., 2005). Approximately 20% of 
chronic HCV cases develop liver cirrhosis, and 2.5% develop HCC (Bowen DG. 
and Walker CM., 2005). HCV-induced hepatocarcinogenesis also provokes 
similar biological processes to that of HBV, but is associated with a propensity 
of HCV to evade the host’s immune responses and to promote cirrhosis (Farazi 
PA. and DePinho RA., 2006). 
 
1.3.2 Alcohol-induced hepatocarcinogenesis 
Alcohol-induced hepatocarcinogenesis is associated with the induction of 
inflammation and, consequently, cycles of hepatocyte necrosis and regeneration, 
oxidative stress and cirrhosis (Farazi PA. and DePinho RA., 2006). Ethanol-
induced oxidative stress might have an effect on HCC-relevant signalling 
pathways (Osna NA. et al., 2005). Oxidative stress might also cause the 
accumulation of oncogenic mutations, for example, mutations in p53 (Marrogi 
AJ. et al., 2001). 
 
1.3.3 Aflatoxin-induced hepatocarcinogenesis 
Aflatoxin B1 is a toxin with mutagenic properties that is produced as a 
secondary metabolite by the fungus Aspergillus flavus, which can contaminate 
many food products such as nuts, spices and oilseeds (Farazi PA. and DePinho 
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RA., 2006). Ingestion of this fungal toxin poses an increased risk for the 
development of HCC. Aflatoxin B1 seems to function as a mutagen, and is 
associated with a specific p53 mutation (Bressac B. et al., 1991; Hsu IC. et al., 
1991; Ozturk M., 1991; Aguilar F., 1994; Ozturk M., 1999). specifically, 
Aflatoxin B1 has been shown to target the third base of codon 249 of the p53 
gene, which underwent a G to C mutaton in a liver-specific manner (Puisieux A. 
et al., 1991).   
 
1.3.4 Other aetiological factors associated with HCC 
In addition to the most common aetiological factors presented in this 
review, other factors have been proposed to have a role in hepatocellular 
carcinoma (HCC) with a lower frequency, including: 
• Long-term oral contraceptive use in women, although a definitive 
connection to the development of HCC will require an expanded study 
(Thorgeirsson SS. and Grisham JW.,  2002). 
• Certain metabolic disorders such as: hereditary haemochromatosis, 
which is associated with increased iron absorption by liver cells and 
hepatocellular damage (Badvie S., 2000; Limdi JK. and Crampton JR., 2004); 
porphyria cutanea tarda, which is also characterized by increased iron uptake in 
the liver, and in some cases is associated with increased inflammation, necrosis 
and fibrosis (Badvie S., 2000; Sarkany RP., 2001); α1-antitrypsin deficiency, 
which involves the increased appearance of antitrypsin polymers in hepatocytes, 
provoking hepatocyte death and cirrhosis (Badvie S., 2000; Parfrey H. et al., 
2003);  and hereditary tyrosinaemia, which involves defects in tyrosine 
metabolism that result in toxic metabolites in the liver with potential mutagenic 
properties (Tanguay RM. et al., 1996; Badvie S., 2000). 
• Diabetes: a higher incidence of HCC has been described in diabetic 
patients with no previous history of liver disease associated with other factors 
(El-Serag HB. et al., 2004). This predisposition might relate to insulin resistance 
and associated increased free fatty acids in the liver and the accumulation of 
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hepatic triglycerides (fatty liver disease). Such intrahepatic accumulation of 
lipids can lead to hepatocellular injury, hepatocyte apoptosis, cytokine induction, 
and oxygen radical generation due to fatty acid oxidation, and ultimately the 
development of fibrosis (Farrell GC. and Larter CZ., 2006). 
• Non-alcoholic fatty liver disorders (NAFLD) and non-alcoholic 
steatohepatitis contribute to the development of fibrosis and cirrhosis, and 
therefore might also contribute to HCC development (Adams LA. and Angulo 
P., 2005; Farrell GC. and Larter CZ., 2006). 
 
1.4 Liver and ER stress  
The ER provides an optimal environment for the synthesis, folding, and 
assembly of membrane and secreted proteins. The accumulation of unfolded or 
misfolded proteins in the ER under conditions of “ER stress” threatens the 
normal functioning of eukaryotic cells (Kokame K. et al., 2001). Although the 
physiological conditions inducing ER stress are not fully understood, the cellular 
response to the stress is essential for homeostasis (Kaufman RJ., 1999). The ER-
stress responses are currently categorized to three mechanisms: transcriptional 
induction, translational attenuation, and degradation (Mori K., 2000). In 
addition, ER stress activates c-Jun Nterminal kinases (Urano F. et al., 2000) and 
induces caspase-12-mediated apoptosis (Nakagawa T. et al., 2000). This stress 
response system, called the unfolded protein response (UPR) or the ER stress 
response, is thought to be conserved from yeast to mammals (McMillan DR. et 
al., 1994; Shamu C. et al., 1994). 
 Hepatocytes contain abundant endoplasmic reticulum (ER) which is 
essential for protein metabolism and stress signaling. Hepatic viral infections, 
metabolic disorders, mutations of genes encoding ER-resident proteins, and 
abuse of alcohol or drugs can induce ER stress. Liver cells cope with ER stress 
by an adaptive protective response termed unfolded protein response (UPR), 
which includes enhancing protein folding and degradation in the ER and down-
regulating overall protein synthesis. When the UPR adaptation to ER stress is 
insufficient, the ER stress response unleashes pathological consequences 
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including hepatic fat accumulation, inflammation and cell death which can lead 
to liver disease or worsen underlying causes of liver injury, such as viral or 
diabetes-obesity-related liver disease (Ji C. and Kaplowitz N., 2006). 
For experimental induction of ER-stress in mammalian cells, a variety of 
chemical agent are used, the most common of which are thapsigargin, 
tunicamycin, brefeldin A. Of these chemical agents, the one with the most direct 
effect on the ER is tunicamycin. Tunicamycin is a mixture of homologous 
antibiotics. It is an inhibitor of bacterial and eukaryote N-acetylglucosamine 
transferases; preventing formation of N-acetylglucosamine lipid intermediates 
and glycosylation of newly synthesized glycoproteins (Dawson RMC. et al., 
1986). It blocks the formation of protein N-glycosidic linkages by inhibiting the 
transfer of N-acetylglycosamine 1-phosphate to dolichylmonophosphate (Heifetz 
A. et al., 1979). It has been shown that tunicamycin induced a programmed cell 
death in plant cells (Crosti P. et al., 2001) and in mammalian cells via 
stimulation of ER stress (Fujita E. et al., 2002).   
 
1. 5 Liver cirrhosis and senescence 
Liver cirrhosis a pathological condition characterized by abnormal liver 
nodule formation and fibrotic scarring of the liver caused by excessive collagen 
deposition after chronic liver disease or damage (Farazi PA. and DePinho RA., 
2006). Cirrhosis is considered a major clinical and histopathological risk factor 
for HCC development (Libbrecht L. et al., 2005). Hepatocyte telomere 
shortening and senescence are general markers of human liver cirrhosis, and 
correlates with progression of fibrosis in cirrhosis samples (Wiemann SU. et al., 
2002). 
 
1.5.1 Cellular senescence 
Cellular senescence was initially defined as the loss of proliferative 
capacity of cells in culture and it results in the inability of the population to 
increase in cell number, typically after cultures have been passaged 50 or more 
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times (Sherwood SW. et al., 1988). Cellular senescence, the state of stable cell 
cycle arrest, can be provoked by a variety of potentially oncogenic stimuli, such 
as telomere shortening, DNA damage or activation of certain oncogenes (Ben-
Porath I. and Weinberg RA., 2004; Campisi J., 2005; Herbig U. and Sedivy JM., 
2006). Senescence is associated with a number of gross cellular changes 
including cell-cycle arrest (Collado M. et al., 2005; Herbig U. and Sedivy JM., 
2006), increase in cell size and size heterogeneity , and increase in the frequency 
of cells with chromosomal aberrations, including polyploidy (Sherwood SW. et 
al., 1988). Senescent cells display SABG (Senescent Associated B-
galactosidase) activity at pH 6.0 and this activity can be used as a marker for 
identifying senescent cells.  Cellular senescence appears to be acting as a barrier 
to cancer, preventing damaged cells from undergoing aberrant proliferation 
(Braig M. et al., 2005; Campisi J., 2005; Chen Z. et al., 2005; Collado M. et al., 
2005; Michaloglou C. et al., 2005; Narita M., Lowe SW., 2005; Sharpless NE. 
and DePinho RA., 2005). Two well established tumor suppressor proteins, pRb 
and p53, have been shown to play key roles in cellular senescence (Ben-Porath I. 
and Weinberg RA., 2004; Campisi J., 2005; Herbig U. and Sedivy JM., 2006). 
 
1.5.2 Replicative senescence and telomere shortening 
Telomeres progressively shorten with age in somatic cells in culture and 
in vivo because DNA replication results in the loss of sequences at the 5' ends of 
double-stranded DNA. Whereas somatic cells do not express the enzyme, 
telomerase, which adds repeated telomere sequences to chromosome ends, 
telomerase activity is detected in immortalized and tumour cells in vitro and in 
primary tumour tissues. This represents an important difference between normal 
cells and cancer cells, suggesting that telomere shortening causes cellular 
senescence (Oshimure M. and Barrett JC., 1997). There is accumulating 
evidence that when only a few telomeres are short, they form end-associations, 
leading to a DNA damage signal resulting in replicative senescence (Shay JW. 
and Wright Woodring E., 2004). This DNA damage signal leads to the activation 
of cell cycle checkpoint pathways involving p53, p16INK4a, and/or 
retinoblastoma (pRb) proteins (Campisi J., 2005; Dimri GP., 2005). It is known 
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that cells acquire replicative immortality by inactivation of p53 and p16INK4a 
genes (Shay JW. and Bacchetti S., 1997) and reactivation of hTERT gene 
expression (Sherr CJ. and  McCormick F.; 2002), as depicted in Figure 1.3. 
 
Shay JW. and Wright WE., 2005 
 
Figure 1.3: Senescence and immortalization: role of telomeres and telomerase. The ectopic 
expression of the catalytic subunit of hTERT results in immortalization of human cells. 
Telomeres are thus important in both senescence (M1) and crisis (M2) as hTERT introduction 
either before M1 or after M1 results in cell immortalization. (Shay JW. and Wright WE., 2005) 
 
1.6 Reprogramming of immortal cell lines for replicative senescence   
Until recently, it was not known whether the immortality feature 
exhibited by cancer cells was a reversible or an irreversible feature. Ozturk N. et 
al. (2005), however, showed that cancer cells with replicative immortality can be 
reprogrammed for replicative senescence.     
 
1.6.1 Induction of Spontaneous Replicative Senescence in HCC-derived 
stable cell lines 
In their work, Ozturk N. et al. (2005) expanded different Huh7-derived 
clones in long-term culture and examined their potential to undergo replicative 
senescence. Through this method, the researchers established two sets of clones: 
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C1/C3-Early/C3-Late and G11/G12-Early/G12-Late clones. The C3 clone 
performed only 80 PD (Population doublings) and was fully SABG positive, 
whereas C1 clone replicated over 150 PD. Early passage C3 (PD 57) cells, like 
the C1 clone, displayed normal morphology with heterogeneous SABG staining. 
Growth-arrested C3 cells displayed very low BrdU staining, in contrast to early 
passage C3 and late passage C1 cells. Similar results were obtained with 
G11/G12 clones. This work showed that replicative immortality, after all, was 
not an irreversible phenomenon and that cancer cells could spontaneously 
generate senescent progeny.    
 
1.6.2 Mechanism of Spontaneous Replicative Senescence in HCC-derived 
stable cell lines  
The immortal C1 clone in the work of Ozturk N. et al. (2005) displayed 
hTERT activity and thus maintained its telomere length, whereas the senescent 
C3 clone displayed no detectable hTERT activity and thus had prominently 
shortened telomeres. Going through the known regulators of hTERT expression, 
the researchers found a perfect reverse correlation between the expression of 
hTERT and that of SIP1 gene (Zinc finger homeobox 1B; ZFHX1B). SIP1 
encodes a transcriptional repressor protein that interacts with SMAD proteins of 
the TGF-B signaling pathway and CtBP co-repressor (Verschueren K. et al., 
1999; Postigo A.A., 2003). The involvement of SIP1 protein as a key regulator 
in this senescence mechanism was further verified by the demonstration of 
bypass of senescence arrest after functional inactivation of SIP expression by 
shRNA in senescence-programmed C3 clonal cells. 
 
1.7 Gene Expression Changes Between Senescent and Immortal Huh7 
clones 
1.7.1 Gene Expression Profiling of Senescent and Immortal Huh7 clones 
In attempt to better understand the differences between the immortal and 
the senescent Huh7 clones, Ozturk M. et al. took a follow-up approach on the 
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work of Ozturk N. et al. (2005). Affymetix gene expression profiling was 
performed on the C1 Immortal/C3 Early Senescent/C3 Late Senescent clones 
and G11 Immortal /G12 Early Senescent/G12 Late Senescent clones and the 
results of this profiling are yet not published. Briefly, 3 copies of each clone 
were grown in a 175cm2 flask and RNA was extracted separately from each 
clone. In this way, no RNA pooling was done and the data could be processed as 
triplicate. For RNA isolation, Promega SV RNA Isolation Kit was employed. 
The samples were treated extensively with DNAse and the obtained RNA 
samples were subjected to quality-assessment using Agilent 2100 bioanalyzer 
and Agilent RNA 6000 Nano LabChip® kit. RNA integrity was found to be 
around 100%, reflecting almost no RNA degradation. cDNA and eventually 
cRNA was synthesized from the RNA samples using the One Cycle cDNA 
Synthesis Kit from Affymetrix. 5 ug of cRNA from each clone was hybridized 
for 16 hours to Affymetrix HGU133Plus2 Chips  (18 chips in total) and the 
signals were detected according to the manufacturer’s protocol.         
 
1.7.2 Analysis of Genes Differentially Expressed Between Senescent and 
Immortal Clones 
After the signals received from the chips were detected, they were 
automatically saved as .CEL files by the Affymetrix Scanner. These .CEL files 
were accessed and processed using ‘R’ software. This tool allowed the 
intensities of the signals received from the chips to be converted into numeric 
expression values of genes. Background correction was performed on this 
expression data using ‘Bioconductor Packages’ in ‘R’ software and 
normalization was performed through ‘RMA’ method . The data was then 
subjected to T-test analysis (two-tailed, unpaired, unequal variance) where the p-
value limit was set to 0.05 (p<0.05). Hierarchical clustering of genes was done 
with GenePattern-software. Finally significant gene lists were obtained that 
contained the names of genes differentially expressed between the early 
senescent, late senescent and immortal clones at a statistically significant level. 
The HGU133Plus2 chip used in this microarray study contains 54675 probes 
corresponding to a total of 47000 transcripts and variants that represent 
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approximately 39000 human genes. In the generation of the significant gene 
lists, the early senescent clones were named as ‘Revertant’ and the late senescent 
clones were named as ‘Senescent’. The final Senescentvs.Immortal significant 
gene list contained 3073 genes represented by 3872 probes, the Revertantvs. 
Immortal significant gene list contained 2149 genes represented by 2552 probes 
and the Senescentvs.Revertant significant gene list contained 2023 genes 
represented by 2388 probes . In total, there were 8812 probes corresponding to 
7245 genes with significantly differential expression (Ozturk M. et al., 
unpublished data).   
 
1.7.3 Identification of FAM134B as a Senescence-Associated Gene    
The Immortal vs. Senescent, Immortal vs. Pre-Senescent and Senescent 
vs. Pre-Senescent significant gene lists were analyzed for genes that were the 
most significantly differentially expressed by looking at the p-value calculated 
for each probe. Some of these genes were already well-known and extensively 
studied, while others were genes the protein products of which were previously 
uncharacterized. Of this latter group, the focus of this study is directed towards a 
gene named FAM134B. FAM134B gene was represented by two probes in the 
gene expression profiling study. According to the probe number 218532_s_at, 
this gene was up-regulated in the senescent clones with respect to the immortal 
clones with a fold change of 6.5 and up-regulated in the senescent clones with 
respect to the revertant clones with a fold change of 2.6. According to the probe 
number 218510_x_at, this gene was up-regulated in the senescent clones with 
respect to the immortal clones with a fold change of 4.9 and up-regulated in the 
senescent clones with respect to the revertant clones with a fold change of 2.8. 
Apparently, FL20152 gene was progressively up-regulated as cells reverted from 
immortality to senescence and was one of the genes that differed the most 
significantly between the three sample types with a p-value of 1.097E-06. Being 
supposedly a senescence-associated gene which hadn’t previously been studied 
in depth, we chose to focus on the characterization of the protein product of this 
gene in this study.    
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CHAPTER 2. OBJECTIVES AND RATIONALE 
 
Hepatocellular carcinoma is among the most lethal and prevalent cancers 
in the human population. Despite its significance, there is only an elemental 
understanding of the molecular, cellular and environmental mechanisms that 
drive disease pathogenesis, and there are only limited therapeutic options, many 
with negligible clinical benefit (Farazi PA. and DePinho RA., 2006). Therefore, 
it is of ultimate importance to come up with new approaches that could open up 
the way to novel therapeutic applications. One finding of the work of Ozturk N. 
et al. (2005) on the reprogramming of immortal cancer cells into replicatively 
senescent progeny is crucial in this respect. In their study, Ozturk et al. (2005) 
injected cells from the immortal C1 clone into one side of a nude mouse and 
cells from the senescent C3 clone into the other side. As expected, it was 
observed that the C1 cells formed readily observable tumors at the site of 
injection. Interestingly, however, the C3 cells failed to form any such tumors, 
indicating that somewhere along the path to replicative senescence program they 
had lost their tumorigenic potential. This observation brought along the question 
of whether it would be possible to design therapies that could revert the immortal 
cancer cells residing in tumors into replicatively arrested senescent cells and 
stop, or at least slow down, liver tumor progression.  
In order to be able to design such smart therapies, one needs to 
thoroughly understand the differences underlying between the immortal and the 
senescent Huh7 clones. In an attempt to assess this difference at the level of 
transcript repertoire, gene expression profiling was performed on immortal and 
senescent clones and a set of genes were identified which are differentially 
expressed between them. Of this significant gene list, in this study we decided to 
focus on a novel gene named FAM134B which is significantly up-regulated in 
the senescent clone with respect to its immortal counterpart. The high fold 
change of this gene suggested that it could be important for the onset of the 
senescent phenotype. This gene was further queried in several HCC arrays 
(which will be further discussed in detail in the ‘Results’ chapter) and it was 
observed that whereas it is a constituent of normal liver, its expression is 
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significantly lost in liver tumors, suggesting a possible ‘tumor-suppression’ 
function. Thus we hypothesized that this gene could be encoding a senescence-
inducing protein product and that, if such was the case, the expression of this 
gene could be manipulated in immortal cells as to drive them into senescence. 
Being a novel gene with an uncharacterized gene product, cloning, localization 
and functional studies were directed towards FAM134B, the results of which 
will be presented in the next section.      
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CHAPTER 3. MATERIALS AND METHODS 
 
3.1 MATERIALS 
 
3.1.1 Reagents 
All laboratory chemicals were analytical grade from Sigma-Aldrich (St. 
Louis, MO, U.S.A), Farmitalia Carlo Erba (Milano, Italy) and Merck (Schucdarf, 
Germany) with the following exceptions: Ethanol and methanol were from 
Riedel-de Haën (Germany). Nucleospin Plasmid mini-prep kit (for small scale 
DNA isolation) was from Macherey-Nagel (Duren, Germany). Qiagen Plasmid 
Maxi-prep kit (for large-scale DNA isolation) and QiaQuick Gel Extraction Kit 
(for recovery and extraction of DNA from agarose gel) were from Qiagen 
(Chatsworth, CA, U.S.A). PureYield Plasmid Midi-prep System kit was from 
Promega (Madison, WI, USA).  Agar, tryptone and yeast extract were obtained 
from Gibco (Carlsbad, CA,USA), BRL Life Technology Inc. (Gaithersburgs, 
MD, U.S.A). Bradford Ready-made Reagent was purchased from Sigma-Aldrich 
(St.Louis, MO,USA). X-gal and IPTG were purchased from MBI Fermentas 
GmbH (Germany).  
 
3.1.2 Bacterial Strains 
The bacterial strain used in this work was: E. coli: DH5α 
 
3.1.3 Enzymes 
Restriction endonucleases used for gene cloning were purchased from 
MBI Fermentas GmbH (Germany). T4 DNA ligase was purchased from 
Promega (Madison, WI, USA).  
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3.1.4 PCR and cDNA synthesis reagents  
For cDNA synthesis, RevertAid First Strand cDNA synthesis kit was used 
(MBI Fermantas, Germany). The reagents used in Polymerase Chain Reaction 
(PCR): Taq DNA Polymerase, 2 mM dNTP, 25 mM MgCl2, 10X Taq DNA 
Polymerase Buffer were purchased from MBI Fermentas GmbH (Germany). 
 
3.1.5 Nucleic acids 
DNA molecular weight standard and ultrapure deoxyribonucleotides were 
purchased from MBI Fermentas GmbH (Germany). pCMV10-3XFLAG and 
pCMV14-3XFLAG plasmids were purchased from Sigma-Aldrich (St. Louis, 
MO, U.S.A). pGEMT-Easy plasmid was purchased from Promega (Madison, 
WI, USA). pEGFPN1 plasmid was purchased from Clontech. 
 
3.1.6 Oligonucleotides 
The primers used in polymerase chain reactions (PCR) for cloning of 
FAM134B isoforms and the oligonucleotides used in the reverse-transcription 
polymerase chain reactions (RT-PCR) of FAM134B in human cell lines and in a 
mouse tissue cDNA panel were purchased from Metabion International AG 
(Martiensried, Germany). The sequencing-primers used for sequence-
verification of engineered constructs and the oligonucleotides used in reverse-
transcription polymerase chain reactions (RT-PCR) of human and mouse 
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) were synthesized by 
İONTEK (Istanbul, Turkey). The sequencing primers CMV24, CMV30 were 
purchased from Sigma-Aldrich (St.Louis, MO, USA)  and T7 and SP6 primers 
were purchased from Promega (Madison, WI, USA). The sequences of the 
primers are given in Table 3.1. 
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Primer ID Sequence (5’  3’) 
FAM134B_1F (Fwd) C CTCGAGAAGCTTATGGCGAGCCCGGCGCCTCC 
FAM134B_2F (Fwd) CTCGAGAAGCTTATGCCTGAAGGTGAAGACTT 
FAM134B_NTR (Rev) GAATTCGGATCCTTAATGGCCTCCCAGCAGAT 
FAM134B_CTR (Rev) GAATTCGGATCCATGGCCTCCCAGCAGATTTG 
FAM134B_FWD1 (Fwd) GCTGTTCTGGTTCCTTGCAT 
FAM134B_FWD2 (Fwd) TCTCCTGGTCTGTAGTGTGT 
FAM134B_FWD3 (Fwd) TCTCAGAGGTATCCTGGACT 
FAM134B_FWD4(Fwd) CTTCCTCTGAACAGTGACCA 
FAM134B_REV1 (Rev) ACCAGCTGCTGATTGCGTCT 
FAM134B_REV2 (Rev) CCGTGAGGCTAATCTTAGGA 
FAM134B_REV3 (Rev) CACTACAGACCAGGAGACAA 
FAM134B_REV4 (Rev) CCATGGAGTCAATGCAAGGA 
CMV30 (Fwd) AATGTCGTAATAACCCCGCCCCGTTGACGC 
CMV24 (Rev) TATTAGGACAAGGCTGGTGGGCAC 
T7 (Fwd) TAATACGACTCACTATAGGG 
SP6 (Rev) ATTTAGGTGACACTATAG 
Table 3.1: The sequences of primers used for cloning and sequencing. Underlined sequences 
represent restriction enzymes sites, italic sequences represent stop codons. Fwd: Forward Rev: 
Reverse 
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3.1.7 Electrophoresis, photography and spectrophotometer 
Electrophoresis grade agarose was obtained from Sigma Biosciences 
Chemical Company Ltd. (St. Louis, MO, USA). Horizontal electrophoresis 
apparatuses were from E-C Apparatus Corporation (Florida, USA). The power 
supply Power-PAC300 and Power-PAC200 was from Bio Rad Laboratories 
(CA, USA). The Molecular Analyst software used in agarose gel profile 
visualizing was from Vilber Lourmat (France). Beckman Spectrophotometer 
Du640 was purchased from Beckman Instruments Inc. (CA. USA) and 
Nanodrop ND-1000 Full-spectrum UV/Vis Spectrophotometer was purchased 
from Thermo Fisher Scientific (Wilmington, DE, USA). 
 
3.1.8 Tissue culture reagents and cell lines 
Dulbecco’s modified Eagle’s medium (DMEM) and trypsin were 
obtained from BIOCHROM (Berlin, Germany) and HyClone (South Logan, UT, 
USA), fetal calf serum was obtained from BIOCHROM AG (Berlin, Germany). 
Penicillin/Streptomycin mixture was from Biological Industries (Haemel, Israel). 
Tissue culture flasks, petri dishes, 15 ml polycarbonate centrifuge tubes with lids 
and cryotubes were purchased from Costar Corp. (Cambridge, England). 
Geneticin-G418 sulfate was purchased from GibcoBRL (Carlsbad, CA, USA), 
Life tech (USA). Tunicamycin was purchased from Sigma-Aldrich (St.Louis, 
MO,USA).  
  
3.1.9 Antibodies and chemiluminescence 
FLAG M2 Mouse Monoclonal Antibody used at a dilution of 1:1000 in 
western-blotting (immuno-blotting) and 1:200/1:1500 in immuno-fluorescence 
was obtained from Sigma-Aldrich (St. Louis, MO, U.S.A).  Calnexin Rabbit 
Polyclonal Antibody used at a dilution of 1:200 in immuno-fluorescence was 
obtained from Sigma-Aldrich (St. Louis, MO, U.S.A). BrdU Mouse Monoclonal 
Antibody, used at a dilution of 1:500 in BrdU incorporation assay, was 
purchased from DAKO (Glostrup, Denmark).  ECL Western Blotting detection 
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kit was purchased from Amersham Pharmacia Biotech Ltd. (Buckinghamshire, 
UK). Anti-mouse TRITC secondary antibody was purchased from Sigma-
Aldrich (St.Louis, MO,USA). AlexaFluor Red 568 anti-mouse and AlexaFluor 
Green 488 anti-rabbit secondary antibodies were purchased from Invitrogen, 
Carlsbad, CA, USA) . 
 
3.1.10 Immuno-peroxidase Staining 
The DAKO EnVision™+ System used in peroxidase staining was 
purchased from DAKO (Glostrup, Denmark).    
 
3.2 SOLUTIONS AND MEDIA 
 
3.2.1 General solutions 
50X Tris-acetic acid-EDTA (TAE):   2 M Tris-acetate, 50 mM EDTA 
       pH 8.5. Diluted to 1X for  
       working solution. 
 
Ethidium bromide:     10 mg/ml in water (stock  
       solution), 30 ng/ml (working 
       solution) 
 
6X Gel loading dye solution:    10mM Tris-HCl (pH 7.6), 0.03% 
       bromophenol blue, 0.03% xylene 
       cyanol, 60% glycerol, 60mM 
       EDTA (0.5M pH8.0) 
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3.2.2 Microbiological media, reagents and antibiotics 
Luria-Bertani medium (LB)    Per liter: 10 g bacto-tryptone, 5 g 
       bacto- yeast extract, 10 g NaCl. 
       For LB agar plates, add 15 g/L 
       bacto agar. 
 
Glycerol stock solution     A final concentration of 25% 
       glycerol in LB was added to  
       bacterial culture   
 
Ampicillin   100 mg/ml solution in double-
  distilled water, sterilized by  
  filtration and stored at -20°C  
  (stock solution).100 µg/ml  
  (working solution) 
 
Kanamycin      300 mg/ml solution in double-
       distilled water sterilized by  
       filtration and stored at -20°C  
       (stock solution). Working  
       solution was 30 µg/ml. 
 
0.1 M IPTG      1.41 g IPTG in 50 ml double-
       distilled water, sterilized by  
       filtration and stored at-20oC.                                 
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Luria-Bertani medium (LB)    Per liter: 10 g bacto-tryptone, 5 g 
       bactoyeast extract, 10 g NaCl. 
       For LB agar plates, 15 g/L bacto 
       agar was added. 
 
SOB medium:      Per liter: 20 g tryptone (2%), 5 g 
       yeast extract (0.5%), 0.584 gr 
       NaCl (10 mM), 0.1864 g KCl 
       (2.5 mM) autoclaved to sterilize. 
       Then, 2.46 g MgSO4 and 2.03 g 
       MgCl2 (10 mM) are added. 
 
SOC medium:      SOB + 20 mM glucose from filter 
       sterilized 1M glucose stock  
       solution in ddH2O. 
 
Transformation Buffer (TB):    10 mM K.PIPES, 55 mM MnCl2, 
       15 mM CaCl2, 250 mM KCl. 
       Filter sterilized and stored at 4oC. 
3.2.3 Tissue culture solutions 
DMEM/RPMI working medium   10% FBS, 1% penicillin /  
       streptomycin, 1% non-essential 
       amino acid were added and stored 
       at 4oC. 
 
10X Phosphate-buffered saline (PBS)   Per liter: 80 g NaCl, 2 g KCl,  
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       14.4 g Na2HPO4, 2.4 g KH2PO4, 
       pH 7.4 
 
Antibiotics 
Geneticin-G418 Sulfate)    500 mg/ml solution in double-
       distilled water. Sterilized by  
       filtration and stored at -20°C  
       (stock solution). 500 µg/ml  
       (working solution for stable cell 
       line selection and maintenance) 
 
Tunicamycin     5mg/ml solution in DMSO.  
       Sterilized by filtration and stored 
       -20°C (stock solution).    
 
3.2.4 SDS (Sodium Deodecyl Sulfate)-PAGE (Polyacrylamide Gel 
Electrophoresis) 
solutions 
30% Acrylamide mix (1:29)    Per 100 ml: 29 g acrylamide, 1 g 
       bisacrylamide in double-distilled 
       water, filtered, degassed, and 
       stored at 4°C (stock solution). 
5X SDS gel-loading buffer    3.8 ml double-distilled water, 1 
       ml of 0.5 M Tris-HCl, 0.8 ml 
       glycerol, 1.6 ml of 10% SDS, o.4 
       ml of 0.05% bromophenol-blue. 
       Before use, β-mercaptoethanol 
       was freshly added  to a final  
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       concentration of 5% to reach 1% 
       when mixed with protein  
       samples. 
 
10X Towbin SDS-electrophoresis buffer  Per liter: 30.3 g Tris base, 144.0 
       g Glycine, 10.0 g SDS. Diluted to 
       1X for working solution.        
       Stored up to 1 month at 4°C. 
 
10% Ammonium persulfate (APS)   0.1 g/ml solution in double  
       distilled water                    
       (Prepared freshly). 
 
1.5 M Tris-HCl, pH 8.8     54.45 g Tris base (18.15 g/100 
       ml) ~150 ml distilled water.  
       Adjust to pH 8.8 with 1 N HCl. 
       Completed to 300 ml with  
       distilled water and stored at 4° C. 
 
1 M Tris-HCl, pH 6.8     12.14 g Tris base ~ 60 ml  
       distilled water. Adjust to pH 6.8 
       with 1 N HCl. Completed to 100 
       ml with distilled water and store 
       at 4° C. 
 
Coomassie brilliant blue solution  Per Liter: 100mg Coomassie 
       brilliant blue G-250, 50ml  
       95% ethanol, 100ml 85%  
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       phosphoric acid. Filtered through 
       whatman paper and stored at 4°C.   
 
 
3.2.5 Immuno-blotting solutions 
Semi-dry transfer buffer    Per liter: 48 mM Tris-base, 39 
       mM glycine, 0.037% SDS, 20% 
       methanol. 
 
10X Tris-buffer saline (TBS)    Per liter: 100 mM Tris-base, 1.5 
       M NaCl, pH 7.6 in double  
       distilled water. 
 
TBS-Tween (TBS-T)     0.5% Tween-20 solution in TBS. 
       (Prepared freshly) 
 
Blocking solution     5% (w/v) non-fat milk, 0.5% 
       Tween-20 in TBS.            
       (Prepared freshly). 
 
3.2.6 Immuno-fluorescence and immuno-peroxidase solutions 
H33258 fluorochrome dye    1 mg/ml solution in double- 
       distilled water and stored at -20 
       °C. Working solution:1µg/ml 
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DAPI (4', 6-diamidino-2-phenylindole)  0.1-1 µg/ml (working solution in 
       PBS). 
 
Blocking solution    5% BSA (bovine serum albumin) 
       in 1X PBS 
 
3.2.7 BrdU incorporation assay solutions 
BrdU stock solution    10 mg/ml BrdU in ddH2O 
 
2N HCl      8.62 ml of 37% HCl, 16.36 ml 
       dH2O  
 
PBS-TritonX-100 (PBS-T)    0.1 TritonX-100 in PBS. 
 
3.2.8 SABG assay solutions 
SABG buffer     40mM citric acid/sodium  
       phosphate buffer (pH 6.0), 5mM 
       potassium ferrocyanide, 5mM 
       potassium ferricyanide, 150mM 
       NaCl, 2mM MgCl2, 1mg/ml X-
       gal 
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3.3 METHODS 
 
3.3.1 General Methods 
 
3.3.1.1 Transformation of E .coli 
Transformation of plasmid DNA into E. coli was achieved by using 
calcium chloride method. Competent E. Coli was prepared by two different 
methods as described below. 
 
3.3.1.2 Preparation of competent cells: Conventional “calcium chloride” 
method 
5 ml LB was inoculated with a single colony from a freshly grown plate 
of E. coli strain (DH5α) and incubated for approximately 2.5 hours at 37oC, 
shaking at 200 rpm to an optical density 0.6 at 590 nm (OD 590). Then, 1.5 ml 
of growing cells was centrifuged at 13,000 rpm for 1 minute in a bench-top 
centrifuge. Excess LB was removed away. The cells were resuspended in 0.5 ml 
of 50 mM CaCl2 by gently vortexing, before being placed on ice for 30 minutes. 
The cells were harvested by centrifugation for 1 minute at 13,000 rpm and the 
supernatant was discarded. The pellet was resuspended in 0.1 ml of 50 mM 
CaCl2 by gently vortexing. At this stage, bacterial cells were competent, and 
transformed as described in 3.3.1.3.1. 
 
3.3.1.3 Conventional “calcium chloride” transformation 
This method was used for transformation of plasmids.20 ng plasmid was 
added to competent cells in 0.1 ml of 50 mM CaCl2 and incubated on ice for 30 
minutes. Then, cells were incubated for 60-90 seconds at 42oC (heat-shock), and 
placed on ice for 2 minutes. 800 µl of pre-warmed LB was added onto cells. 
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Cells were cultured for 1 hour at 37oC with vigorous shaking (200 rpm). After 1 
hour incubation, samples were centrifuged at 13,000 rpm for 30 seconds, and 
excess LB was discarded but leaving approximately 100 µl of LB. The pellet was 
resuspended in the remaining LB. Resuspended bacteria cells were plated out on 
LB-agars with selection agents ampicillin, kanamycin or ampicillin/kanamycin) 
and incubated overnight at 37oC without shaking to allow the growth of the 
transformants. 
 
3.3.1.4 Long term storage of bacterial strains 
To keep bacterial cells including plasmid in it or as empty for future 
experiments and to have a stock of strain in a laboratory is necessary. The most 
frequently used method is “Glycerol-Stock” method. A single colony picked 
from either an agar plate or a loop-full of bacterial stock was inoculated into 5 
ml LB (with a selective agent if necessary) in 15 ml screw capped tubes. Tubes 
were incubated overnight at 37oC and at 200 rpm. For glycerol stock, 500 µl of 
saturated culture was added into 700 ul of 50% glycerol v/v. This mix was 
frozen/stored at –70 or -80oC. 
 
 
 
3.3.1.5 Purification of plasmids 
 
3.3.1.5.1 Purification of plasmid DNA using MN (Macherey-Nagel) 
miniprep kit 
This method was preferred for isolation of plasmids in order to use in 
sequencing or cloning procedures. 5 ml of saturated culture was used for 
isolation of plasmid DNA by using “MN miniprep plasmid DNA purification 
kit” (MN Macherey-Nagel, Duren, Germany) following manufacture’s 
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instructions. The quality of miniprep was checked by loading about 100ng of 
final yields on agarose gel and visualizing under U.V. 
 
3.3.1.5.2 Large-scale plasmid DNA purification (midi-prep) 
This method was used for isolation of plasmids in order to use in 
sequencing or mammalian cell transfection procedures by using “Promega 
PureYield Midi-Prep Plasmid System” following manufacture’s instructions. 
The quality of midiprep was checked by loading about 100ng of  final yields on 
agarose gel and visualizing under U.V. 
 
3.3.1.5.3 Large-scale plasmid DNA purification (maxi-prep) 
This method was used for isolation of plasmids in order to use in 
sequencing or mammalian cell transfection procedures by using “Qiagen large-
scale plasmid DNA purification kit” following manufacture’s instructions. The 
quality of maxiprep was checked by loading about 100ng of final yields on 
agarose gel and visualizing under U.V. 
 
3.3.1.6 Preparation of genomic DNA from cultured cells  
Cultured cells were grown in 100mm tissue culture dishes to 70-80% 
confluency, trypsinized, and washed with 1X PBS. Genomic DNA was isolated 
by using “Zymogen DNA isolation kit” following manufacturer’s instructions. 
 
3.3.1.7 Quantification and qualification of nucleic acids and proteins 
Concentration and purity of the double stranded nucleic acids (plasmid 
and genomic DNAs) and total RNAs were determined by using the ds DNA and 
RNA methods on Nanodrop ND-1000 Full-spectrum UV/Vis Spectrophotometer 
(Thermo Fisher Scientific, Wilmington, DE, USA). Concentration and purity of 
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proteins were determined by using the Beckman Instruments Du Series 600 
Spectrophotometer software programs on the Beckman Spectrophotometer 
Du640 (Beckman Instruments Inc. CA. USA). 
 
3.3.1.8 Restriction enzyme digestion of DNA 
Restriction enzyme digestions were routinely performed in 20 µl or 50 ul 
reaction volumes and typically 5-10 µg DNA was used. Reactions were carried 
out with the appropriate reaction buffer and conditions according to the 
manufacturer’s recommendations. Digestion of DNA with two different 
restriction enzymes was also performed in the appropriate common reaction 
buffer and conditions recommended by the manufacturer.  
 
3.3.1.9 Gel electrophoresis of nucleic acids 
DNA fragments were fractionated by horizontal electrophoresis by using 
standard buffers and solutions. DNA fragments less than 1 kb were generally 
separated on 1.0% or 2.0 % agarose gel, those greater than 1 kb (up to 11 kb) 
were separated on 1 % agarose gels. Agarose gels were prepared by completely 
dissolving agarose in 1x TAE electrophoresis buffer to required percentage in 
microwave and ethidium bromide was added to final concentration of 30 µg/ml. 
The DNA samples were mixed with 5X DNA loading buffer and loaded onto 
gels. The gel was run in 1x TAE at different voltage and time depending on the 
size of the fragments at room temperature. Nucleic acids were visualized under 
ultraviolet light (long wave, 340 nm) and GeneRuler (MBI Fermentas) DNA size 
markers was used to estimate the fragment sizes.1 kb DNA ladder was loaded 
for products sizes of over 1kb and 100 bp ladder for product sizes of below 1kb. 
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3.3.2 Computer analyses 
The sequences of the cloned FAM134B isoforms and of their mouse 
homologues were obtained from NCBI (National Center for Biotechnology 
Information) and UCSC (University of California, Santa Cruz) Genome 
Browser. The exon-intron information of these genes was derived using Ensembl 
Genome Browser at http://www.ensembl.org.  Restriction endonuclease maps of 
the plasmid DNAs were analyzed by using the Clone.exe program. Primers were 
designed by using Primer.exe program provided by Whitehead Institute for 
Biomedical Research. The results of the DNA sequencing of engineered 
constructs were visualized using Finch TV 1.4 available for download at 
http://www.geospiza.com/finchtv.html. The alignments of nucleic acids or protein 
sequence were performed by using the NCBI Blast2Sequences algorithm 
available at the web page http://www.ncbi.nlm.nih.gov/BLAST/ , BIOEDIT 
Sequence Alignment Editor software publicly available at 
http://www.mbio.ncsu.edu/BioEdit/BioEdit.html and ClustalW algorithm 
provided by EMBL-EBI at http://www.ebi.ac.uk/Tools/clustalw2/index.html 
(Thompson JD., Higgins DG., Gibson TJ., 1997).  
For querying FAM134B in HCC microarrays, two databases were used. 
Oncomine- Cancer Profiling Database (Rhodes DR. et al., 2004) can be accessed 
after a free ‘academic’ or ‘non-profit’ registration. FAM134B was queried 
through the ‘Gene Search’ tool on the Oncomine homepage. On the return page, 
clicking on the term matched ‘FAM134B’ takes the user to a new page where 
information on this gene is listed under 5 categories: Summary, Annotation, 
Diff/Ex, C0/Ex and Outlier. For the purposes of this study, ‘Diff/Ex’ was clicked 
and the returned results were filtered by ‘tissue’. Selecting ‘liver’ as tissue and 
viewing ‘differentially-expressed’ genes took the user to a list of 19 liver 
microarrays in which FAM134B displayed differential expression.     
Another database used in this study is OncoDB.HCC- Oncogenomic 
Databas of Hepatocellular Carcinoma (Jou et al., 2007). For querying 
FAM134B, ‘FLJ20152’ (which is an alias of FAM134) was typed in the ‘Gene 
description’ section of ‘Display queried gene and reginal data’ query tool and 
‘region around gene option’ on the left side of the query tool was left as default, 
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+/- 10 Mb (megabases). On the return page, there are two types of data stored. 
Clicking on ‘display region’ gives information on the mapped human markers 
and LOH (loss of heterozygosity) regions around the queried gene. It also lists 
syntenic regions on rat and mouse chromosomes and CGH (comparative 
genomic hybridization) results. Clicking on ‘display data’ gives information on 
differential expression of FAM134B in Stanford HCC microarray data.       
 
3.3.3 Vector construction 
NT-3XFLAG-FAM134B-1 (N-terminal or amino-terminal FLAG tagged) 
and NT-3XFLAG-FAM134B-2 (N-terminal or amino-terminal FLAG tagged) 
vectors were generated by cloning the translated region of the mRNA sequence 
of human FAM134B isoform1 and human FAM134B isoform2 into the HindIII-
BamHI digested p3XFLAG-CMV10 plasmid respectively.  CT-3XFLAG-
FAM134B-iso1 (C-terminal or carboxy-terminal FLAG tagged)  and CT-
3XFLAG-FAM134B-iso2 (C-terminal or carboxy-terminal FLAG tagged)  
vectors were generated by cloning the translated mRNA sequence of human 
FAM134B isoform1 and human FAM134B isoform2 into the HindIII-BamHI 
digested p3XFLAG-CMV14 plasmid respectively. All plasmids were sequence-
verified.        
 
3.3.4 Tissue culture techniques 
 
3.3.4.1 Cell lines and stable clones 
14 HCC derived cell lines (Huh7, FOCUS, Mahlavu, Hep40, Hep3B, 
HepG2, PLC/PRF/5, SK-Hep1, Snu182, Snu387, Snu398, Snu423, Snu449 and 
Snu475) were used in this study, and cultured as described in previously 
(Cagatay T. and Ozturk M., 2002). Breast cancer cell lines MCF-7, MDA-MB-
231, MDA-MB-468, ZR-75-1, MDA-MB-453, CAMA1, SkBR3, MCF12A, 
HCC1937, MDA-157, T-47D (ATCC) and BT-474 (ATCC) and cervical cancer 
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cell line HeLa were cultivated in DMEM. Huh7-derived isogenic clones were 
obtained by G-418 selection after transfection with p3X-FLAG-CMV10 or p3X-
FLAG-CMV10 plasmids. Cells were transfected using Fugene6 Transfection 
Reagent. 48 hours following transfection, cells were trypsinized and re-plated at 
lower density into 100cm plates. Cells were cultivated in the presence of 
geneticin G-418 sulfate (500 µg/ml; GIBCO, Carlsbad, CA, USA) for 30 days 
and isolated single cell-derived colonies were picked up with the help of a 
micropipette tip under microscope light and expanded in the presence of 500 
µg/ml geneticin G-418 sulfate. For experiments where a defined number of cells 
were to be seeded, cell counting was performed.  Following trypsinization, cells 
were resuspended in culture medium and counted manually with a 
hemocytometer.  
 
3.3.4.2 Thawing cell lines 
One vial of the frozen cell line from the liquid nitrogen tank was taken 
and immediately put into ice. The vial was left 1 minute on the bench to allow 
excess nitrogen to evaporate and then placed into 37oC water bath until the 
external part of the cell solution was thawed (takes approximately 1-2 minutes). 
The cells were resuspended gently using a pipette and transferred immediately 
into a 15 ml. sterile tube containing 10 ml cold fresh medium. The cells were 
centrifuged at 1500 rpm at 4oC for 5 minutes. Supernatant was discarded and the 
pellet was resuspended in 10 ml 37oC culture medium to be plated into 100 mm 
dish. After overnight incubation in a humidified incubator at 37°supplied with 
5% CO2, culture mediums were refreshed. 
 
3.3.5.3 Growth conditions of cells 
Dulbecco’s modified Eagle’s medium (DMEM) or RPMI 1640 
supplemented 10% FCS and penicillin and streptomycin (50 mg/ml), and 1% 
NEAA was used to culture the HCC cell lines. The cells were incubated in at 
37°C in an incubator with an atmosphere of 5% CO2 in air.  Empty vector and 
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3X-FLAG-FAM134B expression vector transfected stable clones were cultured 
in parental cell line’s culture medium + 500 µg/ml geneticin G-418 sulfate. The 
cells were passaged before reaching confluence. The growth medium was 
aspirated and the cells were washed once with calcium and phosphate-free PBS. 
Trypsin was added to the flask to remove the monolayer cells from the surface. 
The fresh medium was added and the suspension was pipetted gently to disperse 
the cells. The cells were transferred to either fresh petri dishes or fresh flasks 
using different dilutions (from 1:2 to 1:10) depending on requirements. All 
media and solutions used for culture were kept at 4°C (except stock solutions) 
and warmed to 37°C before use. 
 
3.3.4.4 Cryopreservation of cell lines 
Exponentially growing cells were harvested by trypsinization and 
neutralized with growth medium. The cells were counted and precipitated at 
1500 rpm for 5 min. The pellet was suspended in a freezing solution (10% 
DMSO, 20% FCS and 70% DMEM for adherent cells) at a concentration of 
4x106cells/ml. 1 ml of this solution was placed into 1 ml screw capped-
cryotubes. The tubes were left at -70°C overnight. The next day, the tubes were 
transferred into the liquid nitrogen storage tank. 
 
3.3.4.5 Transient transfection of eukaryotic cells using Fugene 6 transfection 
reagent 
Transfection was performed with Fugene6 Transfection Reagent reagent 
(Invitrogen, Carlsbad, CA, USA) following manufacturer’s instructions. 
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3.3.5 Extraction of total RNA from tissue culture cells and tissue samples 
Total RNAs were isolated from cultured cells using the NucleoSpin RNA 
II Kit (MN Macherey-Nagel, Duren, Germany) according to the manufacturer’s 
protocol. 
 
3.3.6 First strand cDNA synthesis 
First strand cDNA synthesis from total RNA was performed using 
RevertAid First Strand cDNA synthesis kit (MBI Fermantas, Germany). The 
RevertAid kit relies on genetically engineered version of Moloney Murine 
Leukemia Virus reverse transcriptase (RevertAid M-MuLV RT) with low RNase 
H activity. This allows the synthesis of full-length cDNA from long templates. 
The first strand reactions were primed with oligo(dT)18 primer to specifically 
amplified mRNA population with 3’-poly(A) tails. As the reaction conditions 
and components of this kit and those of conventional PCR are compatible, first 
strand synthesized with this system can be used as a template for PCR. 1 to 5 µg 
total RNA was used to synthesize the first stand cDNA following the 
manufacturer’s instruction. After 1:1 dilution of total reaction products in DEPC-
treated water, 2 µl of diluted first strand cDNA was used for PCR. 
 
3.3.7 Primer design for expression analysis by semi-quantitative PCR 
The primer pairs that have been used in expression profile analyses were 
designed carefully. Forward and reverse primer were positioned on different 
exons of the gene of interest, so that the primer pair was either be able to 
produce a longer amplicon from genomic DNA or not be able to amplify from 
the covered genomic DNA region in a given PCR condition (critical parameter 
was extension time). Primers used for expression analysis have been designed 
strictly considering these criteria, and listed in Table 3.2. 
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Table 3.2: RT-PCR primer list. m: mouse  h:human   * mouse homolog of human FAM134B  
 
3.3.8 Fidelity and DNA contamination control in first strand cDNAs 
The fidelity and genomic DNA contamination of first strand cDNAs were 
checked before performing expression analyses. 2µl of diluted first strand cDNA 
was used for cold-PCR amplification of the glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) transcript. GAPDH primer pair for this analysis was 
designed to produce a 151 bp fragment from cDNA and 250 bp fragment from 
genomic DNA. 
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3.3.9 Expression analysis of a gene by semi-quantitative PCR 
 
Determination of optimal cycle of a gene for semi-quantitative PCR 
Using equal amount of templates for PCR amplifications of a gene of 
interest give comparable results at a certain number of PCR cycles. The number 
of optimal PCR cycle was determined by an initial study for each gene by 
performing 35-cycle PCR during which PCR amplicon samples were collected 
by 2-cycle intervals. Agarose gel analysis of samples from 20th, 23rd, 26th, 
29th, 32nd, 35th, 36th 39th, 41st, 43rd, 45th cycles of PCR with an equal load 
defined the minimum number of cycle to visualize the product on agarose gel 
and the saturation cycle. Agarose gels were analyzed by Densitometric 
Fluorescence-Chemiluminescence image analyzer and The Molecular Analyst 
software (BioRad, Hercules,CA,USA). The determined cycle number was used 
for amplification of the gene of interest. 
 
GAPDH normalization 
Equal volume (2µl) of all first strand cDNA samples was used for cold-
PCR amplification of GAPDH transcript using the pre-determined optimal cycle 
number for GAPDH. Then an equal volume of each sample was loaded onto 
agarose gel and intensity of each band was analyzed by Densitometric 
Fluorescence-Chemiluminescence image analyzer and The Molecular Analyst 
software. After intensities were determined, intensity of sample with the highest 
densitometric reading and 2 µl loading volume were used as reference points for 
normalization of input loading volume of other samples for expression analysis 
of both GAPDH and gene of interest by cold PCR amplification. Amplification 
products were analyzed in computer. 
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3.3.10 Crude total protein extraction 
Adherent monolayer cells (both stable and parental cells) were grown to 
70% confluency in growth medium lacking selective antibiotic. After removal of 
growth medium, cells were washed twice with ice-cold PBS to remove any 
serum residue. 400 µl of RIPA lysis-buffer (150 mM NaCl, 50 mM Tris-HCl pH 
8.0, 0.5% sodium deoxycholate, 1 % NP-40, 0.1% SDS and 1X Complete 
Protein Inhibitor mix (Roche, Basel, Switzerland)) was added into 10 cm tissue 
culture petri dish, and cells were scraped with rubber scrapper. Complete lysis 
was achieved by pipetting of crude cell lysates several times and by incubating 
the lysates on ice for 30 min, and then centrifuged at 13.000 G for 30 minutes. 
Total cell protein was collected as supernatant. 
 
3.3.11 Western blotting 
The conventional Bradford protein assay was employed to quantity the 
protein in the lysates obtained from either Crude total. After protein 
quantification, protein lysates were aliquoted into fresh tubes and, stored at –
80°C. 10% resolving gel and 5% stacking gel was used in SDSPAGE analysis of 
protein lysates. EC-120 (E-C Apparatus Corp., Holbrook, NY, USA) and 
ProteanII-xi (BioRad, Hercules,CA, USA) vertical Gel system was set up 
according to manufacturer’s instructions. The standard SDS-electrophoresis 
buffer system was used. Equal amounts of cell lysates were solubilized in 5X 
SDS gel-loading buffer, denatured at 100°C for 5 min and incubated on ice for 2 
min. After a quick spin, samples were loaded onto SDS-polyacrylamide gel. 
After electrophoresis at 80 V for 20 minutes followed by 120 V for 1-2 hours, 
proteins were transferred onto PVDF western blotting membrane (Roche, Basel, 
Switzerland) by using Transblot-Semi Dry (BioRad, Hercules, CA, USA) 
electroblotting apparatus according to the manufacturer’s instructions at 12V for 
45 min for EC-120 gel. Membrane was immediately treated for an hour in 
blocking solution at room temperature and probed with primary antibody either 
for an hour at room temperature or overnight at 4°C. After washing 4 times for 
(5 min, 15 min, 5 min, 5 min) in TBS-T solution at room temperature, the 
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membrane was incubated with appropriate HRP73 conjugated secondary 
antibody for 1 hr. The membrane was washed 3 times for 5 min in TBS-T 
solution at room temperature. After final wash, the blot was exposed to ECL 
western blot detection kit (Amersham, Buckinghamshire, UK) according to 
manufacturer’s instructions. The chemiluminescence emitted was captured on X-
ray film within 30 sec. to 5 min. exposure times. 
 
3.3.12 Immuno-fluorescence 
Autoclaved-sterilized coverslips were placed into the well of 6-multiwell 
plates. 6x104 cells were seeded onto each coverslip and grown overnight in 1 ml 
growth medium. Cells were washed with PBS and fixed in 1 ml of cold methanol 
for 5 minutes. After fixation cells were blocked in 1 ml blocking solution (5% 
BSA in 1X PBS) for 1 hour at room temperature. Coverslips were probed with 
primary antibody in appropriate dilution for 1 hr at room temperature. After 
washing cells twice with 1X PBS, either appropriate TRITC-conjugated or 
AlexaFluor Red/Green secondary antibody was applied for 1 hour at room 
temperature. Cells were washed 2 times with 1X PBS and DNA counter staining 
was performed by with DAPI for 3 minutes. After DAPI was aspirated, 
destaining was done in double-distilled water for 5 minutes. Immediately after 
coverslips were taken out from the well and excess water removed by tissue 
paper, coverslips were mounted onto slides containing DAKO Fluorescent 
Mounting Medium. All steps after the addition of TRITC-conjugated secondary 
antibody or AlexaFluor Red/Green secondary antibody were performed in the 
dark. Stained cells were examined under fluorescence microscope (ZEISS) and 
pictures were captured in a digital ZEISS AxioCam MRc5 camera. 
 
3.3.13 Immuno-peroxidase staining 
Autoclaved-sterilized coverslips were placed into the well of 6-multiwell 
plates. 6x104 cells were seeded onto each coverslip and grown overnight in 1 ml 
growth medium. Cells were washed with PBS and fixed in 1 ml of cold methanol 
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for 5 minutes. After fixation cells were blocked in 1 ml blocking solution (5% 
BSA in 1X PBS) for 1 hour at room temperature. Coverslips were probed with 
primary antibody in appropriate dilution for 1 hr at room temperature. After 
washing cells twice with PBS, DAKO-DAB secondary antibody was applied for 
30 min at room temperature. Cells were washed 2 times with PBS and incubated 
with DAB Chromogen Substrate for 1 min. DNA counter staining was 
performed with Hematoxylene for 1 minute. Hematoxylene was aspirated and 
destaining was done in double-distilled water for 5 minutes. Immediately after 
coverslips were taken out from the well and excess water removed by tissue 
paper, coverslips were mounted onto slides containing DAKO Fluorescent 
Mounting Medium. Stained cells were examined under microscope (ZEISS) and 
pictures were captured in a digital ZEISS AxioCam MRc5 camera. 
 
3.3.14 BrdU incorporation assay 
Sub-confluent cells were labeled with the thymidine analogue BrdU (5-
bromo-2-deoxyuridine) for 4 hours in freshly added culture medium and tested 
as described (Erdal E. et al., 2005). Briefly, cells were washed twice with 1X 
PBS, fixed with 70% ice-cold methanol and washed for 10 minutes with 1X 
PBS. Then the cells were incubated in 2 N HCl for 20 minutes and washed three 
times for 5 minutes with 1X PBS. Following blocking with PBS-T plus 3% BSA 
for 15 minutes, anti-BrdU antibody (Dako) incubation was performed for an 
hour, followed by DAB-ENVISION secondary antibody treatment for 30 
minutes. Following this, cells were incubated with DAB Chromogen substrate 
for visualization.  
 
3.3.15 SABG assay 
SABG activity was detected by using a described protocol (Dimri GP. et 
al., 1995). Briefly, ~20000 cells were seeded in 6-well plates on coverslips. 
After 24 hours, cells were subjected to 5min formaldehyde fixation, followed by 
overnight β-gal buffer incubation at 37ºC. Where B-gal/FLAG immuno-
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peroxidase co-staining was performed, cells were permeabilized with 10 min 
0.25% TRITON-X-100, blocked for 1hour with 5%BSA in 1X PBS. Then 
immuno-peroxidase staining method was employed using α-Flag mouse 
monoclonal antibody. After hematoxylene counterstaining, SABG positive and 
negative cells were identified and counted. 
 
3.3.16 ER-stress experiments 
In ER-stress experiments, 10000 or 20000 cells were seeded in 24 well-
plates. After 24 hours, cells were treated with various concentration of 
tunicamycin (0-12 ug/ml) in DMEM containing 0.2% FCS for an additional 24 
hours. On the next day, cells were washed twice with PBS, fixed with ice-cold 
methanol for 5 minutes and stained with Coomassie Brilliant Blue solution for 5 
minutes. Then cells were washed with PBS, photograpahed using a Nikon digital 
camera and counted under the light of a microscope.   
 
 
3.3.17 Sulforhodamine B (SRB) colorimetric assay for cytotoxicity screening 
The sulforhodamine B (SRB) assay is used for cell density determination, 
based on the measurement of cellular protein content. In this study, this method 
is employed for the toxicity screening of tunicamycin to adherent cells in a 96-
well format. Following 24 hours of tunicamycin incubation period, cell 
monolayers are fixed with 50% (wt/vol) trichloroacetic acid and stained for 60 
min at 4°C, after which the excess dye is removed by washing repeatedly with 
1% (vol/vol) acetic acid. Following air drying of plates, the protein-bound dye is 
dissolved in 10 mM Tris base solution for OD determination at 515 nm using a 
microplate reader. The results are linear over a 20-fold range of cell numbers and 
the sensitivity is comparable to those of fluorometric methods (Vichai V. and 
Kirtikara K., 2006). 
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CHAPTER 4. RESULTS 
4.1 FAM134B   
 
4.1.1 Nucleotide and gene information   
The section cites the information on FAM134B in NCBI (National Center 
for Biotechnology Information)’s ‘Nucleotide’ and ‘Gene’ query databases. The 
name FAM134B stands short for ‘family with sequence similarity 134, member 
B’. Other aliases for this gene are FLJ20152, FLJ22155, and FLJ22179. Its 
NCBI GeneID is 54463. FAM134B nucleotide sequence has been determined as 
part the Human Genome Project (International Human Genome Sequencing 
Consortium, 2004) and also as part of a comparative analysis of human 
chromosome 5 (Schmutz J. et al., 2004). The locus in which FAM134B gene 
resides is named NC_000005 and it corresponds to a 143972 bp linear DNA 
molecule. It has been mapped to the minus strand of the p arm of human 
chromosome 5 and its exact chromosomal location is 5p15.1, with ZNF622 gene 
in the upstream and MYO10 gene in the downstream genomic neighbourhood. 
The following image from the NCBI webpage illustrates the genomic context in 
which FAM134B resides: 
 
Figure 4.1: Genomic Context of FAM134B gene. 
 
FAM134B gene has been classified as a protein-encoding gene. It 
encodes two transcripts: NM_001034850 (gi|77917616) is transcript variant # 1, 
which has a linear full-length mRNA of 3259 bps (basepairs). NM_019000 
(gi|77917615) is transcript variant # 2, which has a linear full-length mRNA of 
3108 bps. The translated region of transcript variant 1 is from base pair number 
39 to 1532, corresponding to a translated mRNA length of 1494 bp . The 
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translated region of transcript variant 2 is from base pair number 311 to 1308, 
corresponding to a translated mRNA length of 998 bp. The two transcripts are 
produced by alternative splicing of exons. Transcript variant 1 consists of 9 
exons of which the first three are unique to this variant. Transcript variant 2 
consists of 7 exons of which the first is unique to this variant. Therefore, the two 
variants have alternatively spliced unique exons in the 5’ region and are 100% 
identical in the 6 exons at the 3’ region. The two variants are depicted as follows 
at NCBI ‘Gene’ webpage: 
 
Figure 4.2: Genomic regions, transcripts, and products of FAM134B gene. 
 
4.1.2 Protein  information  
 
4.1.2.1 General information 
The protein encoded by FAM134B gene is designated as either ‘protein 
FAM134B’ or ‘hypothetical protein LOC54463’. This actually corresponds to 
two protein isoforms translated from the two alternatively-spliced mRNA 
variants, as depicted in the above image. At the beginning of this section, 
information stored on FAM134B protein in the SWISS-PROT Database 
(Bairoch A. and Apweiler R., 1998) will be presented, which will be followed by 
analyses of FAM134B using protein database prediction tools. FAM134B 
protein isoform 1 is represented in SWISSPROT database by Q9H6L5 symbol 
and it consists of 497 aminoacids, corresponding to a molecular weight of 54680 
Daltons and a theoretical isoelectric point (pI) of 4.53. Protein isoform 2 is 
represented by Q9H6L5-2 symbol and it consists of 356 aminoacids, 
corresponding to a molecular weight of 39317 Daltons and a theoretical 
isoelectric point (pI) of 4.39. The isoelectric point, the pH value at which the 
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protein molecule does not migrate, is in the range of pH 5 to 7 for many proteins 
(Encyclopædia Britannica, 2008). The low isoelectric points of these two protein 
isoforms indicate that both are unusually acidic proteins, reflecting a high 
composition of negatively charged residues (over 65 percent).  
The two protein isoforms differ at the N-terminus and are entirely 
identical at the C-terminus.  By similarity, the protein belongs to a family named 
‘FAM134B’ family which is a protein family comprised of members belonging 
to species as diverse as human, mouse, rat, zebra fish, cow and African frog. 
According to SWISS-PROT protein database, evidence for the existence of these 
protein isoforms is only at the transcriptional level and so far, these proteins 
have not been detected or visualized at the translational level. According to 
protein database searches, this protein doesn’t show homology to any known 
functional protein.      
 
4.1.2.2 Protein domain and motif predictions 
  In terms of its sub-cellular localization, FAM134B has been classified as a 
‘potential’ multi-pass transmembrane protein in many protein databases such as 
SWISS-PROT or HPRD (Human Protein Reference Database, Mishra G. et al., 
2006). This classification reflects only the ‘potential’ localization as it has been 
inferred through non-experimental evidence, mainly based on results from 
protein sequence analysis tools and on the presence of alternating hydrophobic 
and hydrophilic amino acid patches along the protein sequence. Furthermore, it 
is not known whether FAM134B potentially localizes to the plasma membrane 
or an organelle membrane. The same databases classify this protein as a 
‘modified’ protein, pointing to a few phospho-specific residues that could be 
targeted by possible phosphorylation events. SwissProt database emphasizes 
serine #276 in isoform1 (corresponding to serine #135 in isoform 2) as such a 
possible phospho-specific residue, as inferred ‘by similarity to other members in  
the protein family’. HPRD predicts serine #211 and tyrosine #218 in isoform 1 
(corresponding to serine #80 and tyrosine #87 in isoform 2) as possible sites of 
phosphorylation based on the idea that there is some logical or conclusive 
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evidence that the given annotation could apply. The exact serine or tyrosine 
kinases that could be recruited to these sites are also not known but are predicted 
by HPRD and SWISSPROT to be Casein Kinase II, PKC (Protein Kinase C), 
PKB (Protein Kinase B) and others. Figure 4.3a and Figure 4.3b illustrate the 
potential transmembrane domains and phospho-residues of both FAM134B 
isoforms as predicted by SWISSPROT’s MotifScan database. 
 
 
 
 
 
 
Figure 4.3a: MotifScan Results of FAM134B isoform 1. * indicates motifs frequently found in 
proteins. The numbers next to each site/domain/region in the legend indicate its position on the 
protein in terms of amino acid numbers.   
 
  
 
 
 
 
 
 
 Figure4.3b: MotifScan Results of FAM134B isoform 2. * indicates motifs frequently found in 
proteins.The numbers next to each site/domain/region in the legend indicate its position on the 
protein in terms of amino acid numbers.      
 
Legend: 1. PHOSPHO-SERINE (By similarity): Serine residue at position 135          
2. VARIANT Q -> E (in dbSNP:rs34432513): non-synonymous SNP at position 238    
3. POTENTIAL TRANSMEMBRANE DOMAIN: 68-88                                   
4*. N-GLYCOSYLATION SITE: 115-118, 119-122                                  
5*. cAMP- AND cGMP-DEPENDENT PROTEIN KINASE PHOSPHORYLATION SITE: 283-286                                                        
6*. CASEIN KINASE II PHOSPHORYLATION SITE: 68-71, 75-78, 80-83, 101-104, 111-114,          
130-133, 158-161, 246-249, 260-263                  
7*. N-MYRISTOYLATION SITE: 230-235
8*. PROTEIN KINASE C PHOSPHORYLATION SITE: 75-77
Legend: 1. PHOSPHO-SERINE (By similarity): Serine residue at position 276
2. VARIANT Q -> E (in dbSNP:rs34432513): non-synonymous SNP at position 379 
3. POTENTIAL TRANSMEMBRANE DOMAIN: 96-116, 119-139, 209-229
4*. N-GLYCOSYLATION SITE: 177-180, 316-319, 320-323
5*. cAMP- AND cGMP-DEPENDENT PROTEIN KINASE PHOSPHORYLATION SITE: 484-487
6*. CASEIN KINASE II PHOSPHORYLATION SITE: 33-36, 149-152, 159-162, 269-272, 276-279, 
281-284, 302-305, 312-315, 331-334, 359-362, 447-450, 461-464
7*. POTENTIAL LEUCINE ZIPPER: 72-93
8*. N-MYRISTOYLATION SITE: 48-53, 216-221, 356-361, 431-436                                                             
9*.PROTEIN KINASE C PHOSPHORYLATION SITE: 88-90, 276-278 
10*.ALANINE-RICH REGION: 2-67
11*.PROLINE-RICH REGION: 4-34
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Apart from these predicted transmembrane domains and phospho-specific 
residues mentioned above, there are no apparent functional or structural domains 
in FAM134B protein. SWISSPROT’s MotifScan and ScanProsite prediction 
tools return a list of motifs that could possibly be found on this protein. 
However, these motifs are those that occur frequently in all proteins and thus 
may not have specificity for FAM134B protein. These motifs include 
glycosylation or myristoylation sites, alanine or proline-rich regions and leucine 
zipper motif. These predicted motifs are also illsutrated for each isoform in 
Figure 4.3a and Figure 4.3b. From these predictions, both FAM134B isoforms 
appear to be potential transmembrane proteins that could be subject to post-
translational modifications. The hydrophobic leucine zipper predicted in isoform 
1 could be employed in dimerization of this protein.     
 
4.1.2.3 SNPs and protein structure of FAM134B 
Ten SNP (Single Nucleotide Polymorphism)s have so far been reported in 
GeneCards database (Rebhan M. et al., 1997)  for FAM134B gene. Of these ten 
SNPs, two are intronic, five are in the UTR regions, two are synonymous and 
only one SNP is non-synonymous. This non-synonymous SNP is a Q 
(Glutamine) to E (Glutamic Acid) aminoacid change at aminoacid position 379 
in isoform 1 (corresponding to position 238 in isoform 2). The minor allele 
frequency of this SNP, according to GeneCards database, is 0.02. The exact 
location of this SNP on FAM134B isoforms has been depicted in Figure 4.3a 
and Figure 4.3b. 
The secondary-structure information of FAM134B isoforms was obtained 
by querying at NPS (Network Protein Sequence Analysis) database using PHD 
(Rost B. et al., 1994), DSC (King RD. and Stenberg MJ., 1996) and MLRC on 
GOR4, SIMPA96 and SOPMA (Guermeur Y. et al., 1999) prediction methods. 
The consensus secondary structure from these three prediction methods indicates 
that FAM134B protein isofroms are predominantly folded into alpha-helices 
with random coils in between and occasionally into extended strands, as depicted 
in Figure 4.4a and 4.4b. 
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Figure 4.4a: Consensus secondary (Sec. Cons.) structure prediction of FAM134B isoform 1   
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 Figure 4.4b: Consensus secondary (Sec. Cons.) structure prediction of FAM134B isoform 2   
  
As for the 3-D structure of FAM134B protein, protein modelling tools fail 
to produce a 3-D structure for FAM134B due to the lack of a homolog with an 
established 3-D structure that can be used as a template by these modelling tools.  
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4.1.3  Gene Homologs and Protein Sequence Conservation 
 
4.1.3.1 Orthologs of FAM134B 
According to HomoloGene Database of NCBI, orthologs of FAM134B 
gene exist in four other species. For FAM134B isoform 1, genes identified as 
putative orthologs of one another and proteins used in sequence comparisons and 
their conserved domain architectures are: 
 
T
a
b
l
e
 
4
.
Table 4.1a: Genes identified as putative    Table 4.1b: Corresponding orthologous  of 
orthologs one another during the    proteins of FAM134B isoform 1 and their of 
construction of HomoloGene for     conserved domain architectures.         
FAM134B isoform 1. 
                                    
 The multiple sequence alignment of the protein sequences of these 
orthologs, generated using ClustalW 2.0.8 (Thompson JD., Higgins DG., Gibson 
TJ., 1997) and showing conserved residues, is given below. The sequnces 
aligned from top to bottom belong to Homo sapiens (human), Rattus norvegicus 
(rat), Mus musculus (mouse), Canis lupus familiaris (dog) and Danio rerio 
(zebrafish) respectively. 
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Figure 4.5: The ClustalW 2.0.8 multiple sequence alignment of FAM13B isoform 1 
orthologs.  
 
The alignment scores revealed by this multiple alignment are given below: 
 
Table 4.2: FAM134B isoform 1 orthologs multiple alignment pair-wise similarity scores 
This alignment indicates that the human FAM134B isoform 1 protein 
sequence is 76 % similar to its dog ortholog, 92% similar to its mouse and rat 
orthologs and 44% similar to its zebrafish ortholog. Of the transmembrane 
domains predicted for FAM134B isoform 1 in MotifScan, the domains between 
amino acid numbers 96-116 and 119-139 are fairly conserved between the five 
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species. The domain between amino acid numbers 209-229 is very highly 
conserved. The Serine residue at position 276, which was proposed as a possible 
phosphorylation site based on predictions of SWISSPROT  database, appears as 
a highly conserved residue which is present in 4 of the 5 species analyzed. In 
zebrafish, this residue has been changed to threonine, another residue that can be 
targeted for phosphorylation by kinases. 
According to UniGene database of NCBI, orthologs of FAM134B 
isoform 2 exist in three other species. Genes identified as putative orthologs of 
one another and proteins used in sequence comparisons and their conserved 
domain architectures are: 
Table 4.3a: Genes identified as putative orthologs    Table 4.1b: Corresponding orthologous 
of one another during the construction of               proteins of FAM134B isoform 2 and 
HomoloGene for FAM134B isoform 2.              their conserved domain architectures. 
    
 The multiple sequence alignment of these orthologs, generated using 
ClustalW 2.0.8 (Thompson JD., Higgins DG., Gibson TJ., 1997) and showing 
conserved residues, is given below. The sequnces aligned from top to bottom 
belong to Homo sapiens (human), Bos taurus (domestic cow), Mus musculus 
(mouse) and Xenopus tropicalis (western clawed frog) respectively. 
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Figure 4.6: The ClustalW 2.0.8 multiple sequence alignment of FAM13B isoform 2 
orthologs. 
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The alignment scores revealed by this multiple alignment are given below: 
 
Table 4.4: FAM134B isoform 2 orthologs multiple alignment pair-wise similarity scores 
 
This alignment indicates that the human FAM134B isoform 2 protein 
sequence is 91% similar to its mouse ortholog, 92% similar to its bovine 
ortholog and 58% similar to its African frog ortholog. The transmembrane 
domain predicted for FAM134B isoform 2 in MotifScan, which lies between 
amino acid numbers 68-88 is very highly conserved between the four species. 
The Serine residue at position 135, which was proposed as a possible 
phosphorylation site based on predictions of SWISSPROT database, appears as a 
highly conserved residue which is present in 3 of the 4 species analyzed. In 
Xenopus tropicalis, this residue has been changed to isoleucine. 
  
4.1.3.2 Paralogs of FAM134B 
FAM134B protein belongs to a protein family named ‘family with 
sequence similarity 134’. There isn’t any data on this family except for a list of 
proteins that belong to this family. Among the human paralogs identified for 
FAM134B by KEGG (Kyoto Encyclopedia of Genes and Genomes) database 
(Kanehisa M. et al., 2004), two are FAM134B family members . These paralogs 
are FAM134A (family with sequence similarity 134, member A) and FAM13C 
(family with sequence similarity 134, member C). Both genes encode single 
isoform, hypothetical proteins. The multiple sequence alignment of the protein 
sequences of these paralogs generated using CLUSTALW 2.0.8 is given below:  
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Figure 4.7: The ClustalW 2.0.8 multiple sequence alignment of FAM13B paralogs. 
The alignment scores revealed by this multiple alignment are given below: 
 
Table 4.5: FAM134B paralogs multiple alignment pair-wise similarity scores. 
 
This alignment reveals that there is 26% percent similarity between 
FAM134B and FAM134A and 33% percent similarity between FAM134B and 
FAM134C. The predicted transmembrane domains display a high degree of 
conservation between the paralogs. The serine residue at amino acid position 
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276, predicted to be phosphorylated, does not show conservation among the 
paralogs.    
And here is the phylogenetic tree of the FAM134 gene family according 
to HOVERGEN database (Duret L. et al., 1999), showing the divergence of the 
gene in vertebrates throughout time: 
 
Figure 4.8: Phylogenetic tree of the FAM134 gene family 
MOUSE: Mus musculus, RAT: Rattus norvegicus 
XENTR: Xenopus tropicalis,  DANRE: Danio rerio   
BOVIN: Bos taurus, TETNG: tetraodon negrovidis 
  
The closest orthologs of human FAM134B gene, according to this 
phylogenetic tree, are bovine, mouse and rat FAM134B genes. The FAM134B 
orthologous genes appear to have diverged from a common ancestor after a 
speciation event and have probably retained the same function in the course of 
evolution. FAM134A and FAM134C, which are the paralogs of FAM134B, are 
also depicted on the phylogenetic tree. These paralogs have little similarity to 
each other, as shown by the above alignment. Thus they are positioned on 
different branches of the phyogenetic tree in Figure 4.8.  They appear to have 
diverged from a common ancestor after a gene duplication event and have 
probably evolved new functions, even if these are related to the original one.     
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4.1.4 FAM134B in Literature 
Since FAM134B is a gene with an uncharacterized protein product, there 
are no research articles listed in ‘PubMed’ and only four research articles listed 
in ‘PubMed Central’ for FAM134B. The first one is an article named 
‘Classification of ductal carcinoma in situ (DCIS) by gene expression profiling’ 
(Hannemann J. et al., 2006). In this article, the authors have studied differences 
in gene expression between different types of DCIS and between DCIS and 
invasive breast carcinomas. In their study, FAM134B is ranked 19 in the list of 
43 genes that are able to discriminate between well- and poorly differentiated 
DCIS. In another article titled ‘Gene expression patterns in blood leukocytes 
discriminate patients with acute infections’ (Ramilo O. et al., 2007), FAM134B 
appears in the list of the 30 classifier genes distinguishing S. aureus from E. coli 
infections. In yet another article named ‘Meta-analysis of human cancer 
microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway’ 
(Wilson BJ. and Giguère V., 2008), FAM134B is referred as a gene that has 
binding sites in its promoter region for ER-alpha but not far GATA3 
transcription factor. Finally, in ‘Aging impacts transcriptomes but not genomes 
of hormone-dependent breast cancers’ article (Yau C. et al., 2007), FAM134B 
appears in the list of differentially expressed genes between  matched estrogen 
receptor (ER)-positive sporadic breast cancers diagnosed in younger (age ≤ 45 
years) and older (age ≥ 70 years) Caucasian women.  
 
4.1.4.1 Transforming capacity of FAM134B 
The physiological role of FAM134B is yet not known. The only report 
focusing on any functional aspect of FAM134B is an article titled ‘Oncogenic 
properties of a novel gene JK-I located in chromosome 5p and its over-
expression in human esophageal squamous cell carcinoma’. This report 
concentrates only on FAM134B isoform 2, and not isoform 1, and  refers to 
isoform 2 as ‘JK-1’, a name that has previously not been designated for this gene 
in any database. The results of this study have shown that of the thirteen ESCC 
cell lines and 30 surgical specimens of ESCC (esophageal squamous cell 
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carcinoma) studied, JK-I was over-expressed in 9 (69%) of the ESCC  cell lines 
and 9 (30%) of the ESCC patient cases. Both NIH 3T3 and HEK 293 cells are 
reported to have acquired the properties of anchorage-dependent and -
independent growth in response to JK-1 was over-expression. Furthermore, the 
researchers observed the formation of subcutaneous sarcomas in all (3/3) the 
athymic nude mice following the subcutaneous injection of NIH 3T3 cells over-
expressing JK-1. The researchers claim that their results indicate that JK-1 is 
commonly over-expressed in ESCC and has a prominent capacity to transform 
normal cells. They emphasize this work as being the first evidence that the over-
expression of JK-1 and its transforming capacity in normal cells may play a 
critical role in the molecular pathogenesis of ESCC (Tang WK. et al., 2007).    
 
4.1.4.2 FAM134B in Gene Expression Profiling Microarrays 
In one microarray study, titled ‘Using a xenograft model of human breast 
cancer metastasis to find genes associated with clinically aggressive disease’ 
(Kluger HM. et al., 2005), FAM134B was identified as a gene with a 
significantly down-regulated expression in a metastatic breast cancer cell line 
with respect to its non-metastatic counterpart, indicating a reverse correlation 
between FAM134B expression and the metastatic process.  
In another study named ‘Anti-proliferative effect of estrogen in breast 
cancer cells that re-express ER (Estrogen Receptor) alpha is mediated by 
aberrant regulation of cell cycle genes’ (Moggs JG. et al., 2005), the expression 
of FAM134B was shown to be significantly up-regulated in response to estradiol 
in MDA-MB-231 cells  that have been engineered to re-express ER-alpha. 
Furthermore, through in silico analysis, three putative ERE (Estrogen Response 
Element) motifs were identified in the promoter of FAM134B.  
In yet another study named ‘Gene expression in human neural stem cells: 
effects of leukemia inhibitory factor (LIF) (Wright LS. et al., 2004)’, the 
researchers used LIF as an agent to prevent the senescence observed when 
human neural stem cells are passaged extensively and they observed an increase 
in the expression of FAM134B in these cells in response to LIF treatment.  
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In the study ‘Expression profiling reveals novel pathways in the 
transformation of melanocytes to melanomas’ (Hoek K. et al., 2004), FAM134B 
was reported to exhibit increased expression as cells transformed from 
melanocytes to melanomas.  
Finally, in the research article titled ‘Discovery of novel methylation 
biomarkers in cervical carcinoma by global demethylation and microarray 
analysis’ (Sova P. et al., 2006), the expression of FAM134B was shown to re-
activated in invasive cervical cancer cell lines in response to treatment with 5-
aza-2'-deoxycytidine and trichostatin A, indicating a possible epigenetic control 
mechanism of FAM134B expression in this system. 
 
4.1.5 Expression Data 
On the UCSC (University of California, Santa Cruz) Genome Browser website, 
the expression data of FAM134B is gathered from several microarray studies. 
The data gathered from the GNF Expression Atlas 1 human data on Affy U95 
chips (Su AI. et al., 2002) , where red represents high expression level and green 
represents low expression level, is as follows:  
 
Error! 
 
 
 
 
Figure 4.9: Expression data of FAM134B based on the GNF Expression Atlas 1 Human 
Data on Affy U95 Chips 
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According to this human expression data, high expression of FAM134B is 
observed in the central nervous system and testis, as wells as in thymus, kidney 
and notably in pancreas. In either adult or fetal liver, there isn’t any apparent 
FAM134B expression.   
 
The data gathered from the GNF Expression Atlas 2 data from U133A 
and GNF1H chips (Su AI. et al., 2004), where red represents high expression 
level and green represents low expression level, is as follows:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: Expression data of FAM134B based on the GNF Expression Atlas 2 Data from 
U133A and GNF1H Chips 
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According to this human expression data, FAM134B shows high 
expression levels in the central nervous system, T-cells, adipocytes, skeletal 
muscle, pancreas and testis cells. On the other hand, low levels of FAM134B 
have been detected in bone marrow, whole blood, lung, kidney, liver and ovary.  
 
4.2 Confirmation of the association of FAM134B gene expression with 
replicative senescence in the Huh7 cell line model system 
Prior to any functional or localization studies, the first step taken was the 
confirmation of the FAM134B gene expression data gathered from the gene 
expression profiling study. For this purpose, RT-PCR was performed on cDNA 
samples prepared from Huh7 C1 immortal, C3 late senescent clones to amplify 
the expressed FAM134B transcripts. The result of this RT-PCR is shown in 
Figure 4.11.   
 
 
 
 
Figure 4.11: FAM134B is up-regulated in senescent clones of Huh7 when compared to their 
immortal counterparts. cDNA representing transcriptome of Huh7 (parental HCC cell line), C1 
(immortal clone) and C3 (senescent clone) were prepared from freshly extracted RNA (1 µg) and 
were used for semi-quantitative RT-PCR experiments. GAPDH: Glyceraldehyde-3-phosphate 
dehydrogenase was used as an internal control. 
 
According to the Figure 4.11, the expression of FAM134B gene is down-
regulated in the C1 immortal clone compared to the parental Huh7 cell line. The 
expression level of the transcript variant 2 is much less than that of transcript 
variant 1 in the C1 immortal clone. In the C3 senescent clone, in contrast, the 
expression of both variants is up-regulated with respect to the parental Huh7 cell 
line, with transcript variant1 displaying a higher expression level than that of 
isoform1 isoform2
GAPDH  
FLJ20152  
Huh7    C1      C3                Huh7    C1       C3
FAM134B
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transcript variant 2.  All in all, these results clearly demonstrate the up-regulation 
of FAM134B in the senescent clones compared to immortal clones.    
 
4.3 FAM134B Expression is down-regulated in liver cancer  
4.3.1 FAM134B in Oncomine database 
Oncomine database is an online cancer gene expression analysis platform 
dedicated to the academic and non-profit research community.  It contains cancer 
microarray data obtained using several tissues (Rhodes DR. et al., 2004). We 
were specifically interested in expression changes of FAM134B in liver arrays 
and according to this database, there are 17 liver arrays in which FAM134B is 
differentially expressed. Of these 17 arrays, FAM134B displays very significant 
(p-value ≤ 0.05) differential expression in one of them. In this study (Chen X. et 
al., 2002), tumor and adjacent non-tumor tissues were collected from HCC 
patients and gene expression profiling was performed on these two sets of 
samples. As shown in Figure 4.12 ,the expression of FAM134B is significantly 
down-regulated (p-value=1.6E-16) in HCC as compared to non-tumor liver.  
 
 
 
 
 
 
 
Chen X. et al. (2002) 
Figure 4.12: Box plot images from Oncomine database displaying progressive down-
regulation of FAM134B in liver cancer.  
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4.3.2 FAM134B in OncoDB HCC Database 
‘OncoDB.HCC’ is a comprehensive oncogenomic database of 
hepatocellular carcinoma (Jou et al., 2007). According to this database, 
FAM134B gene is listed as an HCC-significant gene, as it displays at least 2 
folds expression change in 72% of patients in reprocessed Stanford microarray 
database, deposited here from again the study of Chen X. et al. (2002). Figure 
4.13 illustrates this data, where the gene expression levels have been given in log 
base 2: 
 
The majority of the down-regulation cases occur in HBV+ background, 
with a few displaying down-regulation in HCV+ background or with no virus 
infection at all. Also according to this database, FAM134B gene is located on the 
p arm of human chromosome 5 near a LOH (Loss of Heterozygosity) region.  
These data indicate that whereas normal liver cells express FAM134B protein, 
 
 
 
 
Figure 4.13:  Down-regulated expression of FAM134B in Stanford HCC microarrays. Of the 51-
paired arrays listed in the Standford HCC microarray database, FAM134B displays down-regulation in 36 
of these microarray studies.  
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its expression is lost in liver cancer cells and this loss of expression can be the 
result of loss of heterozygosity at the region around FAM134B gene . It’s 
important to mention that these two features are characteristic of tumor 
suppressor genes. 
 
4.3.3 FAM134B in Wurmbach Microarray Data  
In 2007, Wurmbach et al. published a research article that aimed to 
characterize the molecular events of the hepatocarcinogenic process, and to 
identify new biomarkers for early HCC. In their study, the gene expression 
profiles of 75 tissue samples were analyzed representing the stepwise 
carcinogenic process from preneoplastic lesions (cirrhosis and dysplasia) to 
HCC, including 4 neoplastic stages (very early HCC to metastatic tumors) from 
patients with HCV infection. To have an idea of how the expression of 
FAM134B gene changes in the stepwise hepatocarcinogenic process, we queried 
FAM134B gene in the microarray data of Wurmbach et al.. The mean 
expression values were calculated for the two probes representing FAM134B in 
each disease stage. Furthermore, the different disease stages were merged as to 
end up with a total of five stages. The resulting expression values in log2 for 
different HCC stages are given in Figure 4.14: 
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      Figure 4.14: FAM134B expression in different HCC stages 
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In addition, hierarchical supervised clustering was performed on the data 
of Wurmbach. Following normalization with JustRMA method, the two probes 
representing FAM134B were chosen and hierarchical supervised clustering of 
genes was performed using Average Linkage and One Minus Correlation and the 
following image was obtained:  
      
Figure 4.15: Hierarchical supervised clustering of FAM134B expression in Wurmbach data  
 
It is clear from the graph displaying the expression values and from the 
hierarchical clustering image above that FAM134B gene expression is 
progressively down-regulated as liver disease progresses from cirrhosis to very 
advanced HCC.   
 
4.4 Expression Data of FAM134B 
 
4.4.1 Expression in Mouse Tissues 
Of our initial interest was the tissue distribution of FAM134B gene 
throughout the body. This spatial expression information was gathered by RT-
PCRs that checked the expression of the mouse homolog of FAM134B gene in a 
mouse tissue cDNA panel. The mouse homolog is called Riken cDNA 
1810015C04 gene and like its human counterpart, it encodes two transcript 
variants. Again, like their human counterparts, these two variants are generated 
from a common mRNA by alternative splicing. Therefore, the two variants differ 
in their 5’ exons and are 100% identical in the 6 exons at the 3’ region.   
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The results of the PCR reactions displaying the tissue distribution of 
Riken cDNA 1810015C04 isoforms is given in Figure 4.16: 
 
  
 
Figure 4.8: Riken cDNA 1810015C04 gene expression in mouse tissues mGAPDH: Mouse 
glyceraldehyde 3- phosphate dehydrogenase was used as an internal control. One male and one 
female mouse were sacrificed to generate duplicate data. The tissues were homogenized using a 
Downs homogenizer and subjected to RNA extraction, followed by cDNA synthesis. Some tissue 
samples yielded high quality RNA products, while others suffered from  RNA degradation to 
some extent. Where possible, duplicate PCR reactions were carried out in pairs from the male 
and the female mouse cDNA samples.       
  
According to the above data, the highest expression of the mouse 
homolog of FAM134B is observed in brain, kidney and testis. No expression of 
FAM134B isoform 1 and a low level of expression of FAM134B isoform 2 were 
observed in liver tissue.   
 
4.4.3 Expression in Human Liver and Breast Cancer Cell Lines 
Next, an expression study was carried out where the expression of both 
transcript variants of FAM134B gene were checked in a panel of human liver 
cancer cell lines by RT-PCR. Figure 14 displays this expression data, along with 
the corresponding GAPDH expression levels used for normalization. 
 
 
 
 
 
Figure 4.17: FAM134B expression in human liver cancer cell lines. GAPDH: 
Glyceraldehyde-3-phosphate dehydrogenase was used as an internal control. 
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The same expression study was performed also in a panel of human breast 
cancer cell lines. The results of this RT-PCRs are as below: 
 
 
 
 
 
     Figure 4.18: FAM134B expression in human breast cancer cell lines.     
 GAPDH: Glyceraldehyde-3- phosphate dehydrogenase was used as an internal control. 
 
These expression results show that FAM134B transcript variant 1 is 
apparently more widely expressed among the HCC cell lines analyzed when 
compared to transcript variant 2. The same also holds true for the breast cancer 
cell lines analyzed. Both transcripts show heterogenous expression in HCC and 
breast cancer cell lines. 
 
4.5 Transient ectopic over-expression of FAM134B isoforms  
4.5.1 Transient transfection experiments with vectors encoding FAM134B 
isoforms 
As already mentioned in the Methods chapter, four vectors encoding 
FAM134B isoforms were generated. These vectors are: 
- NT-3XFLAG-FAM134B-1 (N-terminal FLAG tagged FAM134B isoform       
-  NT-3XFLAG-FAM134B-2 (N-terminal FLAG tagged FAM134B isoform 2)    
-  CT-3XFLAG-FAM134B-1 (C-terminal FLAG tagged FAM134B isoform 1      
-   CT-3XFLAG-FAM134B-2 (C-terminal FLAG tagged FAM134B isoform 2)   
Using these circular vectors, along with the circular p3XFLAG-CMV10 
(N-terminal FLAG empty control plasmid) and circular p3XFLAG-CMV14 (N-
terminal FLAG empty control plasmid) vectors, transient transfections were 
performed in Huh7 cells grown on coverslips using Fugene6 transfection 
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reagent. In addition, HeLa cells were transiently transfected with NT-3XFLAG-
FAM134B-2 vector using the same transfection reagent.  
 
4.5.2 Immuno-blotting of FAM134B isoforms in transiently transfected 
Huh7 cells 
Prior to sub-cellular localization experiments, we wanted to verify the 
FAM134B over-expression vectors that we had constructed. Therefore, we 
performed a FLAG immuno-bloting experiment. 48 hours following 
transfection, Huh7 cells transiently transfected with FLAG-tagged FAM134B 
encoding vectors were pelleted and lysed. 30ug of each cell lysate was loaded to 
a gel and blotted with FLAG mouse monoclonal antibody. The result of this 
immuno-staining is given in Figure 4.19: 
 
 
    
 
Figure 4.19: Immuno-blotting results of FLAG-tagged FAM134B isoforms. 
*NT2: NT-3XFLAG-FAM134B-2 vector (N-terminal FLAG tagged FAM134B isoform 2)  
*CT2: CT-3XFLAG-FAM134B-2 vector (C-terminal FLAG tagged FAM134B isoform 2)  
*NT1: NT-3XFLAG-FAM134B-1 vector (N-terminal FLAG tagged FAM134B isoform 1)*CT1: 
CT-3XFLAG-FAM134B-1 vector (C-terminal FLAG tagged FAM134B isoform 1)        
*CMV10: p3XFLAG-CMV10 vector *CMV11: p3XFLAG-CMV14 vector 
 
 
The FLAG antibody produced a single major band for each isoform, 
indicating that it recognized a specific protein. This immuno-blotting data also 
revealed an unexpected result. Whereas the predicted molecular weight of 
FAM134B isoform 1 is 55kD, the band it produced in the western blot represents 
(by comparison to the pre-stained molecular weight marker) a molecular weight 
of over 80 kDa (kilo daltons). Likewise, FAM134B isoform 2 appeared to have a 
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molecular weight of around 60 kDa, whereas its predicted molecular weight is 
only 39kDa. The empty control vectors did not produce any bands, as expected. 
 
4.6 Sub-cellular localization studies of FAM134B protein 
  
4.6.1 FAM134B protein localizes to the ER (Endoplasmic Reticulum) 
After waiting for 48 hours to allow time for protein expression, immuno-
fluorescence staining was performed on HeLa cells transfected, as outlined in 
section 4.4.2, with NT-3XFLAG-FAM134B-2 and pEGFPN1 vectors (to mark 
transfected cells) and this allowed the tracking of N-terminal FLAG tagged 
FAM134B isoform 2 using anti-FLAG mouse monoclonal antibody and DAPI 
for counterstaining. The images obtained at the end of this staining, along with 
the staining from the cells transfected with the empty control vector, are given 
below: 
 
 
 
 
 
 
 
 
Figure 4.20a: Immuno-fluorescence staining results performed on HeLa cells transiently 
transfected with p3XFLAG-CMV10 empty vector (used to detect the background signal from 
anti-FLAG primary antibody) and pEGFP-N1 vector (to mark transfected cells) using anti-
FLAG mouse monoclonal antibody.     
DAPI FLAG
GFP MERGE
40 X 40 X
40 X 40 X
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Figure 4.20b: Immuno-fluorescence staining results performed on HeLa cells transiently 
transfected with NT-3XFLAG-FAM134B-2 vector and pEGFP-N1 vector (to mark 
transfected cells) using anti-FLAG mouse monoclonal antibody.     
The above immuno-fluorescence experiment revealed an asymmetrical, 
perinuclear staining pattern for FAM134B isoform 2. We noticed immediately 
that this staining pattern is very reminiscent of proteins that localize to the ER 
(Endoplasmic Reticulum). If this was the true sub-cellular localization of 
FAM134B, then it would have to co-localize with an ER-resident protein, like 
calnexin. Therefore we designed our next experiment as a FLAG-calnexin co-
immuno-fluorescence staining on Huh7 cells transfected with all FAM134B-
encoding constructs.  
 
4.6.2 FAM134B protein co-localizes with calnexin, an ER resident protein  
Following transient transfection of Huh7 cells with FAM134B-encoding 
constructs, as outlined in section 4.4.2, cells were incubated in a 5% CO2 (carbon 
dioxide) chamber at 37°C for
 
48 hours to allow time for protein expression. At 
the end of this time, immuno-fluorescence staining was performed on these cells 
and N-terminal and C-terminal FLAG tagged FAM134B isoform 1 and isoform 
2 were tracked using anti-FLAG mouse monoclonal antibody, anti-calnexin 
 FLAG DAPI 
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40 X 40 X 
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rabbit polyclonal antibody and using DAPI for counterstaining. The images 
obtained at the end of this staining are given in Figure 4.21:  
 
 
 
 
 
 
 
 
Figure 4.21a: Immuno-fluorescence images of Huh7 cells transfected with p3XFLAG-
CMV10 control vector (used to detect the background signal from anti-FLAG primary 
antibody) 
 
 
 
 
 
 
 
Figure 4.21b: Immuno-fluorescence images of Huh7 cells transfected with p3XFLAG-
CMV14 control vector (used to detect the background signal from anti-FLAG primary 
antibody). 
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Figure 4.21c: Immuno-fluorescence images of Huh7 cells transfected with N-terminal 
FLAG-tagged FAM134B isoform 1 encoding vector. 
 
 
 
 
 
 
 
 
 
 
 
 
      Figure 4.21d: Immuno-fluorescence images of Huh7 cells transfected with                 
     C-terminal FLAG-tagged FAM134B isoform 1 encoding vector. 
 
 DAPI CALNEXIN 
FLAG MERGE 
100 X 100 X 
100 X 100 X 
 DAPI CALNEXIN 
FLAG MERGE 
100 X 100 X 
100 X 100 X 
 73 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.21e: Immuno-fluorescence images of Huh7 cells transfected with  
    N-terminal FLAG-tagged FAM134B isoform 2 encoding vector. 
 
 
 
 
 
 
 
 
 
 
 
 
     Figure 4.21f: Immuno-fluorescence images of Huh7 cells transfected with  
     C-terminal FLAG-tagged FAM134B isoform 2 encoding vector. 
 
 DAPI CALNEXIN 
FLAG MERGE 
100 X 100 X 
100 X 100 X 
 DAPI CALNEXIN 
FLAG MERGE 
100 X 100 X 
100 X 100 X 
 74 
 
In agreement with the results obtained from the FAM134B isoform 2 
staining in the previous experiment, the asymmetrical, peri-nuclear staining is 
observed with all the other constructs. In addition, all FAM134B isoforms 
expressed display complete co-localization with calnexin, reinforcing the 
observation that FAM134B protein localizes to the ER. 
 
4.7 Stable ectopic over-expression of FAM134B isoforms  
For functional studies, we decided to over-express FAM134B in one of 
the liver cancer cell lines in our laboratory. We chose Huh7 cell line for this 
over-expression study as the basal expression level of both FAM134B transcript 
variants are very low in this cell line, as previously shown by RT-PCR 
experiments in Figure 4.17. As explained in the Methods section, Huh7-derived 
isogenic clones were generated that express one of the following vectors: NT-
3XFLAG-FAM134B-1, NT-3XFLAG-FAM134B-2, CT-3XFLAG-FAM134B-
iso-1, CT-3XFLAG-FAM134B-iso-2, p3XFLAG-CMV10 (control) and 
p3XFLAG-CMV14 (control) vectors. 
 
4.7.1 Selection of positive Huh7 clones over-expressing FAM134B protein 
isoforms 
For selection of positive over-expression clones, pellets were collected 
from cells as they were propagated in cell culture. Following lysis of the pellets 
for protein extraction, the clones were screened for positivity by a western blot 
experiment using FLAG mouse monoclonal antibody. The results of this 
screening are below: 
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Figure 4.22: Selection of positive Huh7 clones over-expressing FAM134B protein isoforms 
CMV10: colonies generated with p3XFLAG-CMV10 plasmid, NT1: colonies generated with 
NT-3XFLAG-FAM134B-1 plasmid, NT2: colonies generated with NT-3XFLAG-FAM134B-2 
plasmid, CT1: colonies generated with CT-3XFLAG-FAM134B-1 plasmid, CT2: colonies 
generated with CT-3XFLAG-FAM134B-2 plasmid 
+: positive control lysate of HeLa cells transiently transfected with NT-3XFLAG-FAM134B-2 
plasmid 
+ : indicates positive clones. The molecular weights corresponding to different bands of the 
standard molecular weight marker have been indicated at the right side of each blot.          
 
4.7.2 Selection of positive Huh7 clones with genome-integrated empty vector  
For clones generated with the empty control plasmids, screening was not 
possible by FLAG western blotting as there was no protein with a FLAG eptiope 
that could be recognized by the FLAG antibody. Instead, integration of the 
plasmids into the genome was assessed by screening through genomic DNA 
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extraction from the pellets of the empty control clones, followed by PCR 
analysis using the commercial CMV30 forward and CMV24 reverse sequencing 
primers of the p3XFLAG-CMV10/ p3XFLAG-CMV14 plasmids. The results of 
this PCR screening are given below:  
 
 
       
 
Figure 4.23: Selection of positive Huh7 clones with genome-integrated empty vector +: 
indicates positive clones. PCR was performed using 200ng of genomic DNA from each sample. 
The PCR reaction at the last lane of the gel named ‘CMV14 plasmid’ was performed using 200 
ng of p3XFLAG-CMV14 plasmid as template to serve as a positive control reaction in this PCR 
screening protocol. The positive band appeared around 300bp, as expected.    
 
As revealed by the screening protocols, not all the colonies tested yielded 
positive results. The ratios of total number of clones tested/number of positive 
clones for each construct are listed below: 
- p3XFLAG-CMV10: 5/10 
- p3XFLAG-CMV14: 4/9 
- NT-3XFLAG-FAM134B-1 plasmid: 6/13 
- NT-3XFLAG-FAM134B-2 plasmid: 10/20 
- CT-3XFLAG-FAM134B-1 plasmid: 5/10 
- CT-3XFLAG-FAM134B-2 plasmid: 0/20 
Except for CT-3XFLAG-FAM134B-2 plasmid, positive clones were 
obtained from all constructs. For the next set of experiments, one positive colony 
was chosen from each construct: CMV10-11, CMV14-9, NT1-4, CT1-14 and 
NT2-15. 
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4.7.3 Testing of positive Huh7 FAM134B over-expressing stable clones for 
monoclonality  
Prior to any functional studies, as a final step, the monoclonality of these 
five clones was checked by performing an immuno-peroxidase staining on them 
using a FLAG antibody, followed by hematoxylene counterstaining. Below are 
the results of this immuno-staining experiment: 
 
 
 
 
 
 
 
Figure 4.24: Anti-FLAG immuno-peroxidase staining on Huh7 stable FAM134B over-
expressing stable clones. The brown staining indicates FLAG tagged FAM134B protein in cells. 
The faint staining from CMV10-11 and CMV14-9 clones represent the background staining from 
the FLAG antibody. Counterstaining was performed with hematoxylene. 
 
As can be seen in the above images, the immuno-staining experiment 
revealed 100% positivity for the expression of the FLAG tagged FAM134B 
protein in the clones analyzed. The interpretation of this staining pattern is that 
they are monoclonal, meaning that each clone is single cell-derived.   
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4.8 Functional Studies performed with Huh7 FAM134B over-expressing 
stable clones  
Having identified FAM134B as a protein localizing into the ER, we were 
now interested in elucidating its function in cells. For functional studies, we had 
the FAM134B over-expression clones as a system to use for testing our 
hypotheses on the function of this protein. Since FAM134B gene was identified 
as a senescence associated gene, our first hypothesis was that it had a causative 
role in senescence. In parallel to this, we hypothesized that it would change the 
proliferation rates of cells. Our final hypothesis was that this ER protein had a 
role in regulating the response of cells to ER-stress. Our rationale for forming 
each of these hypotheses as wells as or strategies for testing them will be 
discussed one by one below.    
 
4.8.1 FAM134B over-expression does not induce senescence in Huh7 cells  
Our starting point in choosing to concentrate on FAM134B protein was 
its significant up-regulation in senescent Huh7 clones compared to immortal 
Huh7 clones. Therefore, as a next step in our study, we asked the obvious 
question of whether FAM134B expression caused any changes in the parental 
Huh7 clone in terms of its senescence behaviour. In order find an answer to this 
question, we performed a SABG (Senescence-Associated Beta-Galactosidase) 
assay on the five different afore-mentioned clones, followed by FLAG immuno-
peroxidase staining. Following fixation and subsequent X-gal incubation of the 
cells for 24 hours, they were subjected to immuno-peroxidase staining using a 
FLAG mouse monoclonal antibody. Figure 4.14 displays the results obtained at 
the end of this experiment: 
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Figure 4.25: SABG-FLAG co-immuno-peroxidase staining of Huh7 stable FAM134B over-
expression clones. The brown staining indicates FLAG tagged FAM134B protein in cells. 
Arrows indicate green cells displaying green SABG staining. Counterstaining was performed 
with hematoxylene. 
 
This SABG-FLAG co-immuno-peroxidase experiment revealed a very 
low number of cells that stained positive for SABG activity. These few green 
cells displaying positive SABG index were observed both in clones over-
expressing FLAG-tagged FAM134B protein and in clones expressing the empty 
control vectors and there wasn’t any readily observable difference between the 
SABG indices of the FAM134B over-expressing clones versus the control 
clones. Furthermore, flat, enlarged and multi-nucleated cells reminiscent of the 
senescent cells could be observed both in the over-expression clones and in the 
control clones and not all of these cells displayed positive SABG index. The 
overall results of this experiment indicate that FAM134B overexpression does 
not induce senescence in Huh7 cells.   
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4.8.2 FAM134B over-expression has no effect on Huh7 cell proliferation 
rate  
Having found out that FAM134B protein has no causative role in 
senescence, we asked the next question of whether it has any effect on the 
proliferation rate of cells. In seeking an answer to this question, we performed a 
BrdU incorporation assay on our FAM134B over-expressing clones. We 
incubated our clones with BrdU for 4 hours and performed immuno-peroxidase 
staining using a BrdU mouse monoclonal antibody. Cells that were positive as 
well as those that were negative for BrdU incorporation could clearly be 
distinguished under microscope light. The following figure presents the results 
of this BrdU incorporation assay:    
 
 
 
 
 
 
 
Figure 4.26: BrdU immuno-peroxidase staining on Huh7 stable FAM134B over-expression 
clones. The brown staining indicates BrdU incorporated into the nucleus.  
 
As seen in Figure 4.26, there are a high percentage of cells with positive 
BrdU staining. To assess the difference between the BrdU incorporation rates of 
FAM134B over-expressing clones versus control clones, quantification was 
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CMV10-11 CMV14-9
20X 20X 20X
20X 20X
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performed through manual counting of cells under microscope light. For each 
slide representing one clone, 10 fields were randomly chosen and BrdU positive 
as well as BrdU negative cells were counted. For each field, a BrdU positivity 
percentage was calculated and the means and standard deviations of the 
percentages of these 10 fields were worked out. The resulting quantification data 
is presented below:   
 
 
Figure 4.27: Quantification of BrdU immuno-peroxidase staining on Huh7 stable 
FAM134B over-expression clones.  
 
As can be interpreted from the graph, the BrdU incorporation percentages 
of the different clones are close to each other, except for a slight difference 
between the N-terminal FLAG-tagged FAM134B over-expression clones and the 
corresponding CMV10-11 stable clone. The overall results imply that FAM134B 
over-expression doesn’t have any significant effect on Huh7 cell proliferation. 
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4.8.3 FAM134B over-expression revealed no observable effect on response 
of Huh7 cells to ER-stress  
Previous experiments have demonstrated that FAM134B protein localizes 
to the ER. It The function of ER is to provide an optimal environment for the 
synthesis, folding, and assembly of membrane and secreted proteins. The 
accumulation of unfolded or misfolded proteins in the ER under conditions of 
“ER stress” threatens the normal functioning of eukaryotic cells. It has been 
known for long that hepatocytes contain abundant endoplasmic reticulum (ER) 
which is essential for protein metabolism and stress signaling. It has also been 
known for quite some time that senescent cells have abundant ER activity and 
that secretive pathways undergo dramatic changes in these cells in order to meet 
the high demands of secretion of proteins like inflammatory cytokines, growth 
factors and other molecules that can alter the local tissue microenvironment 
(Campisi J., 2008).  
Based on the above information and the fact that FAM134B expression is 
up-regulated in senescent Huh7 clones, we reasoned that the ERs of these 
senescent cells could be acquiring a new organization with FAM134B protein 
being employed somewhere in this process and that FAM134B over-expression 
could change the response of Huh7 cells to ER-stress. To test this hypothesis, we 
took the approach taken by Delom F. et al. (2007) and treated our FAM134B 
over-expressing Huh7 clones with various doses of tunicamycin, an antibiotic 
that induces ER stress through prevention of formation of N-acetylglucosamine 
lipid intermediates and glycosylation of newly synthesized glycoproteins. Huh7 
FAM134B over-expression clones were seeded into 96 well-plates as triplicate 
and incubated for 24 hours with various doses of tunicamycin. Following this 
treatment, dis-attached cells were washed off with 1X PBS and the extent of cell 
survival was quantified by performing an SRB (Sulforhodamine B) assay on the 
remaining attached cells. Using the Elisa reading values from each well, the 
percent of surviving cells was calculated for each well by dividing the Elisa 
reading of that well to that of the untreated control well. The graph obtained 
from this calculation is given below: 
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Figure 4.28a: Graph representing percentage of cell survival of NT1-4, NT2-15 and their 
control CMV10-11 clone following 24 hour of tunicamycin treatment at different doses. 
Data is derived from triplicate experiment. 0mg/ml cells have been treated with DMSO only. 
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Figure 4.28b: Graph representing percentage of cell survival of CT1-14 and its control 
CMV14-9 clone following 24 hour of tunicamycin treatment at different doses. Data is 
derived from triplicate experiment. 0mg/ml cells have been treated with DMSO only. 
 
According to the above graphs, there doesn’t seem to be a major 
difference between the different clones’ response to ER-stress induced through 
tunicamycin. According to Figure 4.28a, the sensitivity of NT1-4 clone to 
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tunicamycin is not changed compared to that of the CMV10-11 control clone. 
Compared to this same clone, however, the sensitivity of NT2-15 clone to 
tunicamycin shows a slight increase, as revealed by a decrease in cell survival 
percentage. 
According to Figure 4.28b, there isn’t a significant difference between the 
sensitivities of CT1-14 clone and its control CMV14-9 clone to tunicamycin 
treatment. All in all, these experiments indicate that FAM134B over-expression 
has no overall significant effect on the response of Huh7 cells to ER-stress 
induced through tunicamycin treatment. The over-expression of N-terminal 
FLAG-tagged FAM134B isoform 2 causes a  slight decrease in the sensitivity of 
Huh7 cells to tunicamycin, which needs to be verified by further experiments.   
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CHAPTER 5. DISCUSSION AND CONCLUSION 
  
In this study, we focused our attention on a novel gene named FAM134B, 
the protein product of which had previously not been studied in any detail. Our 
starting point for concentrating on this protein is the result of a microarray study 
that was performed by our group (Ozturk M. et al., unpublished data) for 
identifying the gene expression profiling differences between the senescent and 
the immortal Huh7 stable clones established previously (Ozturk N. et al, 2005). 
In the significant gene list representing the most differentially expressed genes 
between these clones, FAM134B appeared as a gene that was significantly (p-
value = 1.097E-06) up-regulated in senescent clones with respect to immortal 
clones. Therefore, we decided to characterize the protein product of FAM134B 
gene in terms of sub-cellular localization and function and in doing so, assess 
any causative role that this protein may have in the senescence programming 
induced in Huh7 cells. 
We started off by verifying the differential expression data of FAM134B in 
our clones. The RT-PCR performed on the cDNA of these clones showed that 
both FAM134B transcript variants displayed down-regulation in immortal clones 
as compared to the parental Huh7 clones and up-regulation in the senescent 
clones as compared to the immortal clones.  We carried on with meta-analysis of 
FAM134B mainly in HCC microarrays and identified FAM134B gene in several 
HCC microarray databases as an HCC significant gene that displayed 
progressive down-regulation in liver disease. It’s not hard to notice that the 
features listed on FAM134B in these databases (progressive down-regulation in 
liver disease, genomic location near a LOH region, down-regulation in HCC 
accompanied by metastasis) are reminiscent of the features a tumor suppressor 
gene. 
As mentioned earlier in the text, there has only been one report published 
on FAM134B protein so far and this report focuses on FAM134B isoform 2 
under the name of ‘JK-1’. In this report, the researchers claim that their results 
indicate that JK-1 is commonly over-expressed in ESCC and has a prominent 
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capacity to transform normal cells. They present their overall results as the first 
evidence that the over-expression of JK-1 and its transforming capacity in 
normal cells may play a critical role in the molecular pathogenesis of ESCC.   
This conclusion is interesting from the point of view that while one protein can 
act as a ‘tumor-suppressor’ in one system,  it can conversely act as an 
‘oncogene’ in another, reflecting the complexity of functional protein 
organization of cells. 
Our next step in this study was to check the expression of FAM134B 
transcript variants in HCC and breast cancer cell lines, as well as in a mouse 
cDNA tissue panel. In the cDNA panel expression study, highest expression was 
observed in brain, kidney, ovary and testis tissues and a low level of expression 
was observed in liver tissue, in agreement with the GNF Expression Atlas human 
data in Figure 4.9 and Figure 4.10. At this point, there comes a question of why 
FAM134B expression is not detected in normal liver, although it’s proposed as a 
potential tumor suppressor. One possible answer to this question is that 
FAM134B expression goes up as cells undergo aging, becoming higher at 
senescence arrest stage. So, we do not detect it easily in young mouse liver. 
Another possible answer is that its expression in humans is different from that of 
mice. In our cDNA panel expression study, for some tissues differences were 
observed between the expression levels from the cDNAs of different genders. 
These expression differences between the two genders in some tissues may be 
due to differential RNA degradation in samples or may reflect differential 
physiological transcriptional regulation events.   
 In the sub-cellular localization studies that we performed with Huh7 cells 
transiently over-expressing FAM134B isoforms, we observed an asymmetrical, 
perinuclear staining for FAM134B protein. Subsequent FLAG-calnexin-co-
staining experiments identified FAM134B as an ER protein. Proteins localized to 
the ER usually have a signal sequence that directs them to the ER during 
intracellular protein transport at or near their N-terminus. Analysis of the 
FAM134B isoform sequences didn’t reveal any such known ER-targeting 
motifs. Such signal peptide motifs are usually cleaved off proteins once they 
enter the ER. Suspecting that FAM134B protein could possess a novel signal 
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peptide for ER targeting and that this peptide could be cleaved off the protein 
once inside the ER, we were worried that the N-terminal flag tag that we fuse to 
this protein could mask such a signal peptide and consequently change the 
protein’s final sub-cellular destination. Therefore, during vector construction, the 
cloning strategy was designed such that FAM134B transcript variants were fused 
to both N-terminal and C-terminal flag tags. In the sub-cellular localization 
experiments, however, no difference was observed between N- and C- terminal 
tagged isoforms, implying that the FLAG tag doesn’t block the proper 
functioning of any ER-targeting signal peptide present in the FAM134B protein 
or doesn’t interfere with the overall folding pattern of the protein to the extent at 
which it changes its final sub-cellular destination.  
Another interesting detail was the observed molecular weights of the two 
FAM134B protein isoforms when they were ran through an SDS-Polyacrylamide 
gel. Whereas the predicted molecular weight of FAM134B isoform 1 is 55kD, 
the band it produced in the western blot represents (by comparison to the pre-
stained molecular weight marker) a molecular weight of over 80 kDa. Likewise, 
FAM134B isoform 2 appeared to have a molecular weight of around 60 kDa, 
whereas its predicted molecular weight is only 39kDa. The FAM134B proteins 
in our over-expression vectors are FLAG-tagged; however, this huge 
discrepancy between the predicted and the observed molecular weights cannot 
be explained merely by the presence of such a small moiety as the FLAG tag. 
The 3X-FLAG tag that is present in our vectors is only 24 amino acids long, 
corresponding to a molecular weight of 2.7 kDa. This discrepancy between 
protein molecular weight and SDS-gel electrophoretic mobility can instead be 
explained by the possible presence of several protein modifications on 
FAM134B protein as predicted by protein analysis tools and databases. Post-
translational modifications like acetylation, myristoylation and glycosylation 
could be adding an extra weight on the protein and also changing its migration 
pattern through an SDS-Polyacrylamide gel. A more plausible explanation is the 
presence of a high number of negatively charged residues on these protein 
isoforms. As mentioned earlier, the isoelectric points of these protein isoforms 
are around 4, which make them unusually acidic. Already carrying an excess 
negative charge, it maybe the case that these protein isoforms cannot bind SDS 
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under the SDS-PAGE conditions and thus, their electrophoretic mobilities can 
only determined by their electrostatic charge and hydrodynamic properties 
(Garcia-Ortega L. et al., 2005).      
As a next step, we established stable cell lines that express FAM134B 
isoforms. Unfortunately, no positive clones could be obtained that stably over-
express the C-terminal FLAG-tagged FAM134B isoform 2. Of the 20 clones 
tested, none gave a positive band in the western blot experiment performed with 
FLAG antibody. We suspected whether there was something wrong with the 
construct that we had generated. However, this was unlikely as all constructed 
vectors were verified through sequencing. Moreover, this construct was used in 
the transient transfection studies of Huh7 cells and produced positive staining in 
the FLAG-calnexin-co-immuno-fluoresence experiment as seen in Figure 4.21. 
Since stable over-expression clones could be obtained with all the remaining 
constructs, this ruled out any possibility that FAM134B over-expression was 
potentially growth restraining and thus was not tolerated by Huh7 cells. Possibly, 
the lack of any positive clones in the 20 clones tested was a pure event of luck, 
meaning that positive clones could be identified if more clones were picked and 
tested. Another possible explanation is that the vector was probably stably 
integrated into the genomes of some of the tested clones; however, since the 
transfected plasmids were delivered in circular format, the integrity of this 
specific plasmid was disrupted inside the cells so that it failed to express the 
desired protein. This problem could be counter-acted by delivering the plasmid 
in an appropriately pre-linearized format. However, due to time constraints, the 
experiments were carried out with the positive clones that were already 
established.      
Next, prior to any functional studies, the monoclonality of the stable 
Huh7 FAM134B over-expression clones was checked because working with 
polyclonal cells could deviate our results. To test this, we performed FLAG 
immuno-peroxidase staining on the clones and observed that all of them 
displayed 100% positive staining pattern, a hallmark of monoclonal cells. In this 
staining experiment, it was apparent that although all cells expressed the 
FAM134B protein, some cells expressed it strongly while others expressed it 
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more weakly. This difference doesn’t reflect polyclonality of these cells but it’s 
rather because the cells are not all in the same phase in their cell cycle. If the 
same staining was performed on previously synchronized cells, a more 
homogeneous staining pattern would be observed in terms of the intensity of the 
FAM134B expression signal. 
In the SABG experiments that were carried out, it was observed that 
FAM134B protein over-expression does not induce senescence in Huh7 cells. 
This finding indicates that over-expressed FAM134B protein does not ‘cause’ 
immortal cells to revert to senescence merely by itself, but also does not rule out 
the possibility that this protein could still be important in the senescence 
program. The up-regulation of FAM134B in the senescent Huh7 clones in the 
study of Ozturk et al. (2005) compared to the immortal clones could be a 
‘consequence’ of the initiated senescence program rather than its ‘cause’ and the 
FAM134B protein could still be performing an important function somewhere 
downstream in this program. Another possible explanation for no observation of 
increased senescence positivity in the stable FAM134B over-expression clones is 
that over-expression of a single protein may not be enough to initiate the 
senescence program and possible partners of FAM134B missing in our 
experimental system and other key players of senescence may be serving here as 
limiting factors.  
Another observation made during the imaging of the FAM134B over-
expression clones was that occasionally enlarged, flattened and multi-nucleated 
cells were seen but that such cells also appeared in the empty vector clones. This 
observation was also recorded for SABG positivity of the clones and both 
observations reflect the normal spontaneous senescence of Huh7 cells, 
reinforcing the conclusion that FAM134B over-expression does not have any 
‘causative’ role in the initiation of the senescence program. Striking here was the 
extremely low number of green (SABG activity positive) cells detected, so low 
that it did not allow any proper quantification study. The low extent of SABG 
positivity in these clones stems from the fact that throughout the antibiotic-
mediated colony selection process, we had specifically been selecting for 
proliferating clones and so that senescent clones were either eliminated from the 
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culture in time or that they were not preferred in the colony picking process 
because of their limited colony size (unless the over-expressed FAM134B 
protein had a strong senescence inducing capacity to make the majority of 
colonies senescent, which was not the case). To complement the SABG staining 
experiment, we also subjected the FAM134B over-expression clones to BrdU 
incorporation assay and found that FAM134B over-expression has no significant 
effect on cell proliferation rates. Taken together, these findings indicate that 
FAM134B over-expression does not induce immediate replicative senescence in 
Huh7 cells. If FAM134B over-expression clones are kept in cell culture for a 
year, however, theoretically SABG staining will display that spontaneous 
senescent cells appear more frequently.   
The final set of experiments compared the responses of FAM134B over-
expression clones and empty vector clones to ER-stress. In these experiments, 
we could not observe an overall effect of FAM134B over-expression on the 
response of Huh7 cells to ER-stress when induced through tunicamycin 
treatment. The over-expression of N-terminal FLAG-tagged FAM134B isoform 
2 caused a  slight increase in the sensitivity of Huh7 cells to tunicamycin, but 
this finding needs to be verified by further experiments. In many instances, 
deregulation of endoplasmic reticulum (ER) homeostasis has been correlated 
with pathologic states and particularly with cancer (Moenner M. et al., 2007). 
Therefore, the increase in the sensitivity of this clone to ER-stress could mean 
that FAM134B isoform 2 signals downstream to a cell death pathway in case of 
too much ER stress and it provides tumor suppression through such a regulation 
of ER stability.  
The lack of any change in the overall response of FAM134B over-
expressing Huh7 cells to ER-stress could be a true finding or it could stem from 
the nature of the agent, tunicamycin, used for induction of ER-stress in our 
experimental system. Since tunicamycin is an antibiotic that induces ER stress 
through prevention of formation of N-acetylglucosamine lipid intermediates and 
glycosylation of newly synthesized glycoproteins and that among the few 
number of motifs that are predicted in protein databases for FAM134B are three 
N-glycosylation sites, there is the possibility that this antibiotic may be affecting 
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the proper folding and final maturation of the FAM134B protein itself. This 
would imply that a high amount of immature FAM134B protein would be 
synthesized by ribosomes but these proteins would fail to become mature, 
functional FAM134B proteins since they would lack the required post-
translational modifications. Therefore, if this were the case, it would not be 
possible to test the true effect of FAM134B over-expression on ER-stress 
induced through tunicamycin since the protein would not be functional in cells. 
To overcome such a potential limitation, the effect of FAM134B over-expression 
on the response of Huh7 cells to ER stress could be tested by employing other 
known ER-stress inducers that have a less dramatic effect on ER and that act 
through rather more indirect ways. Unless these additional experiments prove 
otherwise, the possibility that FAM134B protein isoforms are employed in tumor 
suppression through the maintenance of ER stability still exists.   
One interesting aspect of our findings is that FAM134B protein isoforms 
do not possess any known ER localization sequences per se, yet they can 
successfully be imported into the ER, probably into the ER membrane, to be 
more specific. This implies that these protein isoforms employ alternative ways 
for their intra-cellular import. A search for proteins that can locate to the ER 
without a signal peptide sequence returned a protein family named ‘Reticulon 
family’. This family of proteins have been shown to associate with the ER 
membrane through a motif called a ‘reticulon motif’. Reticulon motif contains 
two large hydrophobic regions separated by a 66 residue hydrophilic segment. 
The hydrophobic portions are supposed to be membrane-embedded and the 
hydrophilic 66 residue localized to the lumenal/extracellular face of the 
membrane, acting as a loop in between the two transmembrane domains. (Van 
de velde HJ. et al., 1994; Roebroek AJ. et al., 1996; Roebroek AJ. et al., 1998; 
GrandPre T. et al., 2000). A single reticulon homology domain (RHD) 
hydrophobic region was shown to be sufficient to target an enhanced green 
fluorescent protein–reticulon fusion protein to the ER, wheras deletion of the 
RHD abolished association with the ER (Chen MS. et al., 2000; Iwahashi J. et 
al. 2007).  
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Interstingly, reticulon motif was predicted by MotifScan in the protein 
sequence of FAM134B protein isoform 1, and also predicted by KEGG SSDB 
when searched among Pfam domains. This predicted motif appears to span the 
protein from amino acid number 82 to amino acid number 279, as shown in 
Figure 5.1.  
 
 
Figure 5.1: MotifScan prediction of ‘reticulon motif’on FAM134B isoform 1 protein 
sequence. 
 
The extent of homology between reticulon motif and the 82-279 amino 
acid region of FAM134B isoform is not very strong. The e-value of the 
alignment as predicted by MotifScan is 0.0015. Although much amino acid 
identity has been lost over the course of evolution, the overall structure of the 
reticulon homology domain has been preserved from plants to yeasts to humans. 
This suggests that three-dimensional protein structure is of greater importance 
than individual residues for reticulon homology domain function (Yang Y. and 
Strittmatter SM., 2007). Therefore, the reticulon homology motif predicted in 
FAM134B isoform 1 sequence may be a true and functional motif, even though 
it does not display exact sequence conservation with the hyper-conserved 
residues within the reticulon homology domain. Figure 5.2 illustrates an 
alignment between the 82-279 amino acid region of human FAM134B isoform 1 
and a selection of vertebrate reticulons from rat, mouse, human and also a 
reticulon from C.elegans.  
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Figure 5.2: The ClustalW 2.0.8 multiple sequence alignment of vertebrate  
reticulons and FAM13B isoform 1 predicted reticulon homology domain. 
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In this alignment, the amino acid residues have been coloured by their 
hydrophobicity, where hydrophobic residues are coloured with red and 
hydrophilic residues are coloured with blue. This allows to visualize the first 
hydrophobic (red) region which shows a high degree of conservation and 
corresponds to the first transmembrane region, followed by the hydrophilic 
(blue) region which shows a low degree of conservation and corresponds to the 
loop region and finally the second hydrophobic (red) region which shows a very 
high degree of conservation and corresponds to the second transmembrane 
domain. This is in agreement with the information that across phyla, the second 
hydrophobic region of the reticulon homology domain is the most highly 
conserved, followed by the first hydrophobic region, with the carboxy terminus 
the least conserved (Yan R. et al., 2006). Reticulon motif is located at the very 
C-terminus of reticulon family of proteins. FAM134B isoform 1 differs from the 
reticulon family in this respect, as the reticulon motif is located rather closer to 
the N-terminus, between amino acids 82 and 279 of the full-length 497 amino 
acid sequence (Figure 5.2).     
Since the alternatively spliced form FAM134B isoform 2 lacks the initial 
141 amino acids of FAM134B isoform 1, it does not possess the entire RHD 
domain. It contains only the second hydrophobic region of the RHD domain and 
it is predicted as a single-pass transmembrane protein. In our experiments, it was 
shown that this isoform localizes to the ER as well, indicating that the single 
hydrophobic region of the RHD domain is sufficient to embed this isoform into 
the ER membrane.  
In an attempt to verify the membrane association of the potential RHD 
predicted on FAM134B isoforms, we used the DAS transmembrane prediction 
server (Cserzo M. et al., 1997) publicly available at 
http://www.sbc.su.se/~miklos/DAS/ and determined the overall hydrophobic 
properties of both FAM134B isoform 1 and isoform 2. These hydrophobicity 
plots are given in Figure 5.3: 
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Figure 5.3:  Predicted hydrophobicity plots of FAM134B isoform 1 and isoform 2. The x-
axis represents the amino acid residues in the protein sequences. The y-axis represents each 
residue’s probability of being embedded in the membrane or its hydrophobicity. The dashed line 
and the straight line are loose and strict cutoffs, respectively. 
 
The hydrophobicity plots given above indicate that FAM134B isoform 1 
has two hydrophobic regions, the amino acid positions of which correspond to 
the predicted reticulon motif. The plot given for FAM134 isoform 2 illustrates 
that this isoform possesses a single hydrophobic region, which corresponds to 
the second hydrophobic region of the reticulon homology domain. It is clear 
from the two plots that the two isoforms differ in their hydrophobicity at their N-
terminus sequence, where they are alternatively spliced from a common mRNA, 
and they are totally identical starting form amino acid number 151 in isoform 1 
and amino acid number 11 in isoform 2. 
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The membrane topologies of reticulon proteins are so far only partially 
defined. In parallel to this partial information, we predicted the membrane 
topologies of FAM134B isoform 1 and isoform 2. These predicted topologies are 
given in Figure 5.4: 
 
      
Figure 5.4: Possible membrane topologies of FAM134B isoform 1 and isoform 2.  
The double arrows mean that ER lumen and cytoplasm can switch places, indicating that 
  there are actually two conformations possible for each isoform. The illustration has been 
  modified from Yang YS. and Strittmatter SM. (2007). 
 
It is also noteworthy to mention that isoelectric points of reticulon family 
of proteins are around 4, meaning that, like the FAM134B protein isoforms, they 
are unusually acidic. Another similarity between reticulon family of proteins and 
FAM134B protein is that both are alternatively spliced, generating multiple 
isoforms with different N-terminal sequences and identical C-terminal 
sequences. In contrast to the highly conserved carboxy terminal RHD, the 
amino-terminal regions of reticulons display no sequence similarity at all, even 
among paralogs within the same species. The divergent reticulon amino-terminal 
domains appear to carry out species-and cell-specific roles, whereas the RHD 
may carry out more basic cellular functions (Yan R. et al., 2006).  
The functional motif of reticulon proteins is the reticulon motif (Oertle T. 
et al, 2003). There is growing evidence that reticulons are involved in bending 
and shaping of the ER membrane, in trafficking of material from the ER to the 
Golgi apparatus, and in apoptosis. Reticulons interact with proteins involved in 
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vesicular formation and fusion such as SNAREs and SNAPs, pointing to a role 
in intracellular trafficking (Yang YS. and Strittmatter SM., 2007).  Reticulon 1C 
(RTN1C) was found to inhibit Bcl-XL and reticulon 4A (RTN4A) was found to 
inhibit both Bcl-XL, and another apoptosis inhibitor, Bcl-2, demonstrating a pro-
apoptotic role for reticulons (Tagami S. et al., 2000). Furthermore, reticulon 3 
(RTN3) was shown to mediate Bcl-2 accumulation in mitochondria and its 
expression was shown to be up-regulated in response to endoplasmic stress (Wan 
Q. et al., 2007). The reticulon gene family is based on a cellular component 
ontology i.e. proteins are considered to be members of the family if they contain 
at least part of an identifiable reticulon homology domain (Oertle T. et al, 2003). 
Since FAM134B isoform 1 contains such a homology domain, it can be 
speculated that FAM134B is employed in cellular functions similar to those 
attributed to reticulons. Roles in apoptosis and maintenance of ER stability have 
already been proposed for FAM134B based on the results of this study. Whether 
FAM134B is involved in such functions and whether it can be classified as a 
novel reticulon family member can only be concluded in the light of additional 
biological evidence.           
 All in all, our results shed light on many aspects of the novel FAM134B 
protein and provide the first evidence that both isoforms of this protein localize 
to the Endoplasmic Reticulum. The up-regulation of FAM134B expression upon 
the initiation of the senescence program in Huh7 cells has been described for the 
first time in our study, adding to the chains of indirect evidence reported for the 
expression changes of FAM134B in numerous micro-array studies mentioned 
earlier in the text. The expression levels of FAM134B protein isoforms have 
been checked in several HCC and breast cell lines and mouse tissues and the 
function of FAM134B protein has been tested through several experiments in the 
stable over-expression clone system, making this the only study that ever focuses 
on the characterization of both isoforms of FAM134B protein. Our results are 
important in terms of addressing and understanding the basic differences 
between the senescent and immortal Huh7 clones, which need to be worked out 
in detail before they can be manipulated for designing therapeutic applications of 
senescence programming in HCC.                      
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CHAPTER 6. FUTURE PERSPECTIVES 
 
Our work has identified FAM134B as a senescence up-regulated gene 
encoding two ER protein isoforms. As a short-term follow-up of our study, 
experiments that should be performed for confirmation of preliminary data are 
summarized below: 
 
- Firstly, verification of the ER localization of FAM134B protein 
isoforms is required. This can be done by performing ER fractionation on 
FAM134B over-expression clones, followed by anti-FLAG western blotting on 
the ER fraction. 
 
- For confirmation of the ER localization, tracking of the endogenous 
protein is also a necessity. FAM134B antibody is now commercially available 
and it can be used in immuno-fluorescence or immuno-peroxidase experiments 
to track the exact sub-cellular localization of FAM134B protein isoforms.   
 
- Our findings on the response of Huh7 cells over-expressing FAM134B 
isoforms to ER-stress need to be confirmed. Due to the direct and drastic affects 
of tunicamycin on protein modification and maturation, the ER-stress 
experiments need to be repeated with other stress inducers such as MG132 (a 
proteasome inhibitor), methanesulfonic acid methyl ester (MMS) (a DNA 
alkylating agent), A23187( an ER Ca2+-ATPase inhibitor) or thapsigargin (a  
lumenal Ca2+ mobilizing agent).  
 
- The functional tests performed with FAM134B over-expression clones 
need to be checked with FAM134B shRNA-mir down-regulation clones. 
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The long-term follow- up experimental strategy to be taken for this work 
is summarized below: 
 
- The apparent tumor-suppressor features of FAM134B in HCC can be 
checked by testing the expression of FAM134B isoforms in HCC tumors and 
adjacent non-tumor tissues. 
 
- Since the functions of FAM134B isoforms have yet not been assessed, 
additional functional assays for detecting altered growth characteristics in vitro 
of tumor features can be performed and the results from over-expression and 
control clones can be compared. These assays include, but are not limited to, 
anchorage-independent growth assay as colony formation in soft agar and 
contact inhibition growth assay as foci formation. 
 
- The in vivo tumorigenicity of FAM134B over-expression can be 
assessed by injection of over-expression and control clones into nude mice. 
 
- Possible protein partners of FAM134B protein isoforms can be 
identified by performing an IP (immuno-precipitation) or a Yeast-2-hybrid assay  
 
- The existence of the predicted transmembrane domains, motifs and 
modification sites can be verified by using deletion and point mutation 
constructs and modification-specific antibodies     
 
- FAM134B was shown to be re-activated in invasive cervical cancer 
cell lines in response to treatment with 5-aza-2'-deoxycytidine and trichostatin A 
(Sova P. et al., 2006). Whether this possible epigenetic control mechanism of 
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FAM134B expression exists also in the liver cancer cell line system can be 
checked.  
 
- In one microarray study, the expression of FAM134B was shown to be 
significantly up-regulated in response to estradiol in MDA-MB-231 cells that 
have been engineered to re-express ER-alpha. Furthermore, through in silico 
analysis, three putative ERE (Estrogen Response Element) motifs were 
identified in the promoter of FAM134B (Moggs JG. et al., 2005). The response 
of FAM134B expression to estradiol in the breast cancer cell line system can be 
studied in detail and the existence of these putative ERE sites can be tested by 
deletion constructs.    
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